Preface

The Gladys M Brawn Memorial Bequest was established to provide a permanent memory of Mr Harold Brawn’s late wife Gladys. The Deeds purpose is to grant fellowships to scholars who have demonstrated the potential to become world recognised academics or clinicians in medicine or in disciplines related to medicine in order to promote research and study in that particular field or discipline.

In the past year two fellows were appointed, Professor Murray Cairns, Senior Brawn Fellow and Dr Chris Williams, Career Development Fellow. An outline of their research and achievements can be found further in this report.

In 2018 our Fellows have achieved significant results both with grant success, HDR student supervision and publications. They have achieved international awards and recognition and continued their appointments on boards and societies of international ranking and relevance.

The 2017 interest allocation to The Gladys M Brawn Bequest was $462,445 (for use in 2018). The final closing balance of the Brawn Bequest was $10,636,158 as at 31 December 2017.

The 2018 interest has been confirmed at $329,628 (for use in 2019). The bequest earnings will support current commitments coupled with funding from the Faculty of Health and Medicine.

The gravesite of Gladys M Brawn was last visited on the 2 November 2018 and was in good condition and upkeep.
Contents

Gladys M Brawn Bequest Rule .................................................................................................................. 3
  1. Introduction ........................................................................................................................................ 5
  2. Rule Intent .......................................................................................................................................... 5
  3. Rules .................................................................................................................................................... 5
  4. Relevant Definitions ............................................................................................................................. 12

Summary of Gladys M Brawn Fellowships Awarded 1998 - 2018 ......................................................... 13

Gladys M Brawn Memorial Fellow Reports ............................................................................................ 21
  Professor Dirk van Helden ..................................................................................................................... 22
  Professor Xu Dong Zhang ....................................................................................................................... 24
  Professor Amanda Baker ......................................................................................................................... 27
  Professor Kypros Kypri .......................................................................................................................... 32
  Professor Geoff Isbister .......................................................................................................................... 35
  Professor Philip Hansbro ......................................................................................................................... 38
  Professor Clare Collins ............................................................................................................................ 45
  Professor Frances Kay-Lambkin ............................................................................................................... 52
  Professor Murray Cairns .......................................................................................................................... 57
  Professor Billie Bonevski ......................................................................................................................... 60
  Dr Chenchen Jiang ................................................................................................................................. 64
  Dr Vanessa Murphy ................................................................................................................................. 66
  Dr Christopher Williams ........................................................................................................................... 69

Gladys M Brawn Bequest Financial Report ............................................................................................. 73

Gladys M Brawn Gravesite ....................................................................................................................... 75

Glossary of Terms ....................................................................................................................................... 77
Gladys M Brawn Bequest Rule

(Note: Endorsed by Executive Committee 4 August 2014 and pending Council approval)
GLADYS M BRAWN BEQUEST RULE – 000136 – TO BE APPROVED

Date of first edition: <completion by policy team>
Date this review will take effect: <completion by policy team>
Date of next Review: <completion by policy team>

TRIM Folder Ref: <completion by policy team>
Document Number: <completion by policy team>
Revision Number: <completion by policy team>

Approved by, date: The University Council
Rule Sponsor: The University Council

Governing Legislation:

Supporting documents, procedures & forms of this Rule: Deed of the Brawn Bequest

Subordinate Policies:

Audience:

Keywords: Bequest, Fellowship, Memorial, Gift Committee,

Important Notes: This Rule replaces the Rules Governing Gladys M Brawn Memorial Gift Committee - Rule
1. **Introduction**

The Gladys M Brawn Memorial Fellowship Scheme (Scheme) was established in 1995. It provides fellowships to scholars who demonstrate the potential to become world recognised academics or clinicians in medicine or in disciplines related to medicine, in order to promote research and study in that particular discipline. The Scheme is a result of the generous donations to The University of Newcastle, through the Faculty of Health and Medicine, from the late Leslie Harold Brawn in memory of his wife Gladys M Brawn. The terms of the Gladys M Brawn Memorial Bequest (Brawn Bequest) are determined by a Deed (attachment 1) established in 1993 and the conditions of the Deed make it essential that the Brawn Bequest be established in perpetuity.

2. **Rule Intent**

This Rule is created in accordance with the terms of the Deed of the Brawn Bequest which state that the Council must constitute the Gladys M Brawn Memorial Gift Committee (Gift Committee) (clause 6.2) who has the responsibility to administer the income received from the fund, and must adopt a set of rules for the conduct of its business (clause 6.4) which must be approved by the Council.

3. **Rules**

3.1 **The Committees**

3.1.1 **The Gift Committee**

3.1.1.1 Establishment

The Gift Committee was established by the Council at its June 1995 meeting held on 8 December 1995, to administer the income received from the Capital Fund. The composition of the Gift Committee, and its responsibilities are specified in section 6 of the Deed.

3.1.1.2 Purpose and responsibilities

a. In accordance with section 6.5 of the Deed, the purpose and responsibility of the Gift Committee are to:

i. establish and administer the Fellowship to attract researchers in Medicine or disciplines related to Medicine; and

ii. nominate recipients for the Fellowship to the Council.

b. The Gift Committee will:

i. determine the manner in which the availability of the Brawn Fellowship will be advertised, including the vehicles for its announcement, and the country or countries in which such availability will be advertised;

ii. determine the criteria to be applied in the selection of the successful candidate for the Brawn Fellowship, having regard to the provision in section 3 of the Deed, that those selected must demonstrate "the potential to become world recognised academics or clinicians in medicine or in disciplines related to medicine in order to promote research and study in that particular field of discipline";

iii. determine the duration of the Brawn Fellowship in respect of each candidate recommended to the Council;
iv. determine the manner in which the availability of the Brawn Fellowship will be advertised, including the vehicles for its announcement, and the country or countries in which such availability will be advertised;

v. determine the criteria to be applied in the selection of the successful candidate for the Brawn Fellowship, having regard to the provision in section 3 of the Deed, that those selected must demonstrate "the potential to become world recognised academics or clinicians in medicine or in disciplines related to medicine in order to promote research and study in that particular field of discipline";

vi. determine the duration of the Brawn Fellowship in respect of each candidate recommended to the Council;

vii. determine the conditions under which a Brawn Fellowship may be held and, if the Brawn Fellowship is to be available to any particular candidate over a specified period subject to the satisfaction of certain criteria, what those criteria are to be.

viii. In making nominations for award of the Brawn Fellowship, the Gift Committee will take such expert advice as it can reasonably obtain (including consultation by the Pro Vice-Chancellor (Health and Medicine) with the Professors of the Faculty of Health and Medicine, as to the relative merits of the applicants and of the research projects which each applicant proposes.

3.1.1.3 Membership

a. As provided under section 6.3 of the Deed, the Gift Committee shall comprise the persons for the time being holding the positions of:

i. the Vice-Chancellor, the University of Newcastle;

ii. the Pro Vice-Chancellor (Health and Medicine), the University of Newcastle;

iii. the Mayor of the City of Newcastle;

iv. the Member of Parliament for the State Seat of Newcastle (or such electorate that includes the Central Business District of the City of Newcastle);

v. the Editor of the leading Newcastle daily newspaper;

vi. the Manager of the leading Newcastle commercial television station;

vii. the Regional Director or the Deputy Regional Director of the Hunter Region of the New South Wales Department of Health.

b. The Gift Committee will:

ix. decide who the persons are, from time to time, who occupy the positions defined in section 3.1.1.3a. above;

x. select a substitute person of near description, near interest or near background in respect of each vacancy arising from time to time caused by any of the office-holders described in section 3.1.1.3a. above being unable or unwilling to accept appointment to the Gift Committee; and

xi. decide any dispute as to the membership of the Gift Committee.

3.1.2 The Investment Committee

3.1.2.1 Establishment

The Investment Committee is established by the Deed.

3.1.2.2 Purpose and Responsibilities
The Committee recommends the University to:

a. Invest and administer the Bequest fund in accordance with the UON Investment Policy, as updated from time to time, and

b. All investment and administration actions be carried out in accordance with the UON Delegation of Authority Policy, as updated from time to time.

3.1.2.3 Membership

As provided under section 9 of the Deed, the Investment Committee shall comprise the persons for the time being holding the positions of:

1. Vice Chancellor of the University of Newcastle;
2. University Secretary of the University of Newcastle;
3. Chief Financial Officer of the University of Newcastle;
4. Dean of the Faculty of Health and Medicine of the University of Newcastle.

3.1.3 Common Committee Rules

3.1.3.1 Frequency of Meetings

a. The Gift Committee shall meet as frequently as is necessary for it to fulfil its purpose and responsibilities, but not less than once in each calendar year.

b. The Investment Committee shall meet annually and at least one week prior to the Gift Committee.

3.1.3.2 Quorum

The quorum for meetings of the Gift Committee and Investment Committee shall be three.

3.1.3.3 Reporting

The Committees shall report to the Council after each meeting.

3.2 The Fellowship

3.2.1 General

3.2.1.1 It is a requirement of the Deed that Brawn Fellowships be advertised nationally and internationally each year.

3.2.1.2 Although it is expected that most Senior Fellow candidates will be attracted by personal contact, advertising will raise the profile of the Brawn Bequest and Brawn Fellowship Scheme and reflect the status of the University of Newcastle as a place for high quality research.
In making recommendations for a Brawn Fellowship, the Gift Committee takes into account expert advice from the Pro Vice-Chancellor Faculty of Health and Medicine concerning the relative merits of the applicant and the projects proposed. The level of funding provided for each type of Brawn Fellowship (See Section 3.2.2) will be reviewed annually by the Gift Committee and adjusted accordingly.

3.2.2 Fellowship Funding

3.2.2.1 Yearly expenditure is budgeted based on the annual projected interest earnings from the Capital Fund provided by the Accountant. The annual projected interest is the amount that can be expended in the current year to create and support Brawn Fellowships. The net funds available each year are determined after the deduction of annual grant-in-aid support for eligible Research Fellows and other relevant commitments (for example, gravesite upkeep, advertising).

The Gift Committee has the discretion to allocate up to 15% of the interest earned for Capital Fund preservation therefore maintaining the Capital Fund.

3.2.2.2 Fixed Term Fellowship

When an award is made for a fixed term Fellowship (Post-Doctoral or Strategic) the total expenditure for the entire duration of the award (e.g. 2 or 3 years) is committed from the interest earned on the Capital Fund in the year that the Brawn Fellowship is awarded, so that no further financial obligation is required from the Brawn Bequest in subsequent years.

3.2.2.3 Continuing Fellowships

a. When an award is made for a continuing Fellowship (Senior Research Fellowship) the grant-in-aid and salary gap top-up allocation is budgeted as an annual commitment from the available funds each year for as long as the Brawn Fellow remains eligible for the grant-in-aid.

b. When surplus Faculty funding is available, the Gift Committee approved that the Faculty of Health and Medicine will co-support existing Senior Research Fellows in order to free up the interest earned for the recruitment of new Senior Fellows. In this instance, the Faculty of Health and Medicine will fund the grant-in-aid and salary gap top-up for all existing Senior Research Fellows and the automatic recruitment of University of Newcastle staff who achieve a renewable externally funded fellowship (in line with the intent of the Deed). The Brawn Bequest will continue to underwrite the salary Reserve Fund for all Senior Research Fellows.

3.2.2.4 Reserve Fund

a. The Senior Research Fellow’s salary Reserve Fund (up to $300,000) is retained within the Capital Fund in order to maximise interest earnings. The commitment of funds to comprise the Reserve Fund can be made at any time as long as the Senior Research Fellow is assured of being able to access the Reserve Fund should circumstances require it.
Senior Research Fellow’s requesting access to their Reserve Fund are to make any such requests in writing to the Gift Committee.

The Reserve Fund is in place for a time determined by the Gift Committee to offset the need to fund the Senior Research Fellow in the event that external funding is no longer made available.

If a Senior Research Fellow requires the use of the Reserve Fund, the grant-in-aid allocation is suspended until external funding is secured. Full Reserve Fund provisions are to be set aside prior to a Senior Research Fellow needing to access the funds (at end of first renewable period). The committed amounts are held in a separate Brawn ‘non-active’ account for reporting purposes and/or until required by the Senior Research Fellow.

3.2.2.6 To track expenditure for individual Brawn Fellows a separate cost centre is established for each Brawn Fellow with a budget indicated to limit expenditure to the amount awarded. The funds are transferred as at 31 December each year to maximise interest earnings.

3.2.2.7 Annual investment earnings which are not committed in any given year are returned to the Capital Fund for further investment.

3.2.2.8 If commitments are no longer required (e.g. Reserve Fund provision, funds committed for recruitment of Brawn Fellow(s)), the Gift Committee decides whether to roll the excess funds back into the Capital Fund or utilise them for further recruitment opportunities in the following year.

3.2.3 Fellowship Types

3.2.3.1 Senior Research Fellows

The principal aim of the Brawn Bequest is to support Senior Research Fellows of the highest possible calibre who will add strategic value to the research profile of The University of Newcastle. Senior Fellows are expected to either bring their own renewable salary support or obtain renewable external salary support within 5 years. Normally Senior Fellows will be appointed full-time.

Senior Research Fellows with their own renewable salary support will receive:

i. a grant-in-aid of $35,000 per year (or other amount to be determined from year to year).

ii. a Reserve Fund of up to $300,000 to provide salary support for up to 2 years should their external salary support fail to be renewed.

iii. a contribution (up to a maximum of 50%) towards any salary gap between the remuneration provided by the external salary and the University of Newcastle salary rate for the level of appointment of the Senior Research Fellow.

iv. and by negotiation may receive a start-up package up to the value of $500,000.

Senior Research Fellows who do not initially bring their own salary support but who represent strong potential to do so, and whose appointment would have particular strategic value to the Faculty of Health and Medicine, may be provided with a salary for up to 5 years without the annual grant-in-aid. When external salary support is secured the extra benefits above will apply.
d. The use of the grant-in-aid funds will be at the discretion of the Senior Research fellow; part or all of it can be used as a non-superannuable salary supplement for the Senior Research Fellow or in any way to advance the research program of the Senior Research Fellow (e.g. salaries for staff, scholarships, travel, equipment). Any equipment purchased must remain the property of the University of Newcastle. The grant-in-aid must be spent in the year that it is committed, unless written permission is granted by the Gift Committee to roll over the funds. However a 10% carry forward is allowable without prior written approval. This carry forward figure is not cumulative.

e. In the case of strategic recruitment of exceptional senior researchers to a Senior Research Fellow appointment, the Gift Committee has the ability to make decisions on recruitment to attract and retain such individuals. The appointment must be in line with the Deed’s intent and enhance the research capacity of the University of Newcastle and the Faculty of Health and Medicine. Where a Fellowship position is created and the recruitment process is ongoing, the Gift Committee has the authority to commit funds to the Fellowship.

3.2.3.2 Career Development Fellows

a. Fellowship Category 1

a. The Career Development Fellowship scheme supports early and mid-career researchers who hold non-renewable external fellowships by providing the security of a salary Reserve Fund (1st year guaranteed and 2nd year based on performance) and a grant-in-aid of $20,000 for each year of the Career Development Fellowship, to use towards research expenses.

b. The grant-in-aid is funded from the Faculty of Health and Medicine’s annual budget and must be spent in the year in which it is committed to the Career Development Fellow, unless written permission is granted by the Pro Vice-Chancellor (Health and Medicine) prior to year end.

b. Fellowship Category 2

i. To support and foster early- to mid-career researchers (less than 15 years post-doc) to build research trajectory, the Brawn will provide a ‘buy-out’ scholarship that assists in reducing teaching commitments so recipients can concentrate on research outputs.

ii. The Fellowship will provide a maximum of $30,000 per annum (actual amount will be dependent on interest earnings from year to year) to assist with this buy-out over a three (3) year period. Any unused funds cannot be rolled over to a future year.

iii. It is expected that after the three years of support from the Brawn Trust, the Fellow will remain as a UON research academic for at least a further three year period.

iv. Reporting during the fellowship period will be required and yearly renewal will be contingent on sufficient outputs being achieved.

v. Subject to performance, this fellowship category can be renewed for one (1) further funding period. Requests must be made in writing to the Brawn Gift Committee.

c. General

a. Previously appointed Career Development Fellows may apply for a Senior Research Fellowship.
3.2.3.3 Post-Doctoral Fellows

a. Whilst the funding of Senior Research Fellows is a priority, funds may also be used to support high quality Post-Doctoral researchers. Post-Doctoral Fellows will receive up to 3 years salary support (at an Academic Level A or Level B Salary rate) plus a grant-in-aid of $10,000 per annum towards research expenses. Post-Doctoral Fellows must have the potential to obtain external salary support and will be expected to apply for this support in the first and subsequent years of the fellowship and sacrifice the Brawn Fellowship if and when successful.

b. The grant-in-aid must be spent in the year that it is committed, unless permission is granted by the Gift Committee to roll over the funds.

c. A current Post-Doctoral Fellow whose fellowship is less than 3 years can apply, as part of a normal competitive application round, to have the Post-Doctoral Fellowship extended up to a maximum of 3 years. Researchers who have previously held a Post-Doctoral Fellowship cannot apply for a second Post-Doctoral Fellowship.

d. Previously appointed Post-Doctoral Fellows may apply for a Career Development Fellowship and/or a Senior Research Fellowship.

3.2.4 Reporting

3.2.4.1 Each Brawn Fellow must acknowledge support from the Gladys M Brawn Memorial Fellowship Scheme in all publications arising from and during the tenure of the fellowship and be prepared to promote the memory of Gladys M Brawn in relevant media when required.

3.2.4.2 Each Brawn Fellow must submit an annual report through the Faculty of Health and Medicine to the Gift Committee.

3.2.4.3 The Faculty of Health and Medicine will prepare a composite Brawn Fellowship Annual Report every year. This Report will be provided to the Council.

3.2.4.4 In accordance with the Rules Governing Gladys M Brawn Memorial Gift Committee 000136, the Gift Committee will report to the Council following each meeting.

3.3 Fellow Leave Arrangements

3.3.1 Leave Arrangements

3.3.1.1 As a University of Newcastle academic staff member all Brawn Fellows are entitled to leave arrangements in accordance with The University of Newcastle Academic Staff Workplace Agreement found at http://www.newcastle.edu.au/service/leave-management/leave-management-resources.html.

3.3.1.2 Returning to work on a part-time basis is also allowable subject to approval by the Gift Committee following the submission of a written request that:
a. Specifies the proposed period of part-time Brawn Fellowship;
b. Describes how the research program of the Brawn Fellow can still meet its objectives despite the Brawn Fellow being part-time; and
c. Outlines the arrangements made to ensure that research program meets its objectives while the Brawn Fellow is part-time.
d. The Brawn Fellowship and grant-in-aid will be suspended whilst leave is taken and will be reactivated when the Brawn Fellow returns to work. The duration of the Brawn Fellowship will remain as awarded or adjusted on a pro-rata basis if the Fellow returns to work part-time.

4. Relevant Definitions

In the context of this document:

Accountant - the University of Newcastle financial services staff member assigned the responsibility of administering the financial operations of the Gladys M Brawn Trust Account.

Brawn Fellow - individual awarded a Fellowship established in accordance with the provisions of the Deed.

Brawn Fellowship - Gladys M Brawn Memorial Fellowship awarded in accordance with the provisions of the Deed.

Capital Fund - original gift donation from the late Leslie Harold Brawn and accrued amounts held in a trust account by the University of Newcastle.

Commitment/committed - funds allocated by the Gift Committee and awarded to the successful Fellow or Fellowship for the purposes of the Fellowship.

Council - the University of Newcastle Council.

Deed - the Gladys M Brawn Memorial Trust Deed signed and sealed on 12 February 1993.

Reserve Fund - commitment of funding set aside for the salary of Fellows in the event that external funding is no longer made available.

Trust - wishes of the late Leslie Harold Brawn relating the amounts donated which are held and managed by the University of Newcastle.
Summary of Gladys M Brawn Fellowships
Awarded

1998 - 2018
## Summary of Fellowships Awarded 1998 – 2018

### Senior Brawn Fellows

<table>
<thead>
<tr>
<th>Name</th>
<th>Year Commenced</th>
<th>External Fellowship title</th>
<th>Total Research Income for Fellowship Period (HERDC figures provided from 2007 to 2017)</th>
<th>Indicative Research Earnings 2011-2018 (Derived from HERDC Income)</th>
<th>Total Fellowship Payments to date (Grant in Aid, Salary Contribution, Reserve Fund)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor Dirk van Helden</td>
<td>1998</td>
<td>NHMRC Principal Research Fellow (previously)</td>
<td>$2,325,910</td>
<td>$559,722</td>
<td>$713,800</td>
</tr>
<tr>
<td>Professor Amanda Baker</td>
<td>2009</td>
<td>NHMRC Senior Research Fellow</td>
<td>$4,508,964</td>
<td>$1,188,660</td>
<td>$500,000</td>
</tr>
<tr>
<td>Professor Kypros Kypri</td>
<td>2013</td>
<td>NHMRC Senior Research Fellow</td>
<td>$1,654,598</td>
<td>$427,065</td>
<td>$305,000</td>
</tr>
<tr>
<td>Professor Geoff Isbister</td>
<td>2014</td>
<td>NHMRC Senior Research Fellow</td>
<td>$3,966,676</td>
<td>$856,738</td>
<td>$250,000</td>
</tr>
<tr>
<td>Professor Phil Hansbro</td>
<td>2015</td>
<td>NHMRC Senior Research Fellow</td>
<td>$8,763,280</td>
<td>$2,052,911</td>
<td>$200,000</td>
</tr>
<tr>
<td>Professor Clare Collins</td>
<td>2016</td>
<td>NHMRC Senior Research Fellow</td>
<td>$2,376,840</td>
<td>$305,197</td>
<td>$150,000</td>
</tr>
<tr>
<td>Professor Frances Kay-Lambkin</td>
<td>2016</td>
<td>NHMRC Senior Research Fellow</td>
<td>$1,444,940</td>
<td>$80,160</td>
<td>$125,000</td>
</tr>
<tr>
<td>Professor Murray Cairns</td>
<td>2017</td>
<td>NHMRC Senior Research Fellow</td>
<td>$1,706,294</td>
<td>$130,110</td>
<td>$35,000</td>
</tr>
</tbody>
</table>

### Previous Senior Brawn Fellows

<table>
<thead>
<tr>
<th>Name</th>
<th>Period</th>
<th>External Fellowship title</th>
<th>Total Funding Awarded</th>
<th>Total Publications</th>
<th>Total Fellowship Payments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor Derek Laver</td>
<td>2001 – 2008</td>
<td>ARC Research Fellow</td>
<td>$3,188,212</td>
<td>160</td>
<td>$268,663</td>
</tr>
<tr>
<td>Emeritus Professor Leonie Ashman</td>
<td>2002 – 2011</td>
<td>NHMRC Principal Research Fellow</td>
<td>$11,518,101</td>
<td>231</td>
<td>$302,329</td>
</tr>
<tr>
<td>Professor David Pow</td>
<td>2004 – 2007</td>
<td>NHMRC Senior Research Fellow</td>
<td>$2,376,534</td>
<td>Data not available</td>
<td>$60,000</td>
</tr>
</tbody>
</table>
### Career Development Fellows - Category 1

<table>
<thead>
<tr>
<th>Name</th>
<th>Period</th>
<th>External Fellowship title</th>
<th>Total Research Income for Fellowship Period</th>
<th>Indicative Research Earnings 2011-2018</th>
<th>Total Fellowship Payments to date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Associate Professor Billie Bonevski</td>
<td>2013 – 2017</td>
<td>NHMRC Career Development Fellow</td>
<td>$3,568,109</td>
<td>$692,232</td>
<td>$187,000</td>
</tr>
<tr>
<td>Professor Mark Parsons</td>
<td>2014 – 2016</td>
<td>National Heart Foundation Fellow</td>
<td>$3,457,955</td>
<td>$803,332</td>
<td>$40,000</td>
</tr>
<tr>
<td>Associate Professor Luke Wolfenden</td>
<td>2015 – 2017</td>
<td>NHMRC Career Development Fellow</td>
<td>$5,041,535</td>
<td>$832,633</td>
<td>$80,000</td>
</tr>
<tr>
<td>Dr Chenchen Jiang</td>
<td>2015 – 2018</td>
<td>NSW Cancer Council Career Development Fellow</td>
<td>$1,311,342</td>
<td>$151,210</td>
<td>$80,000</td>
</tr>
<tr>
<td>Dr Vanessa Murphy</td>
<td>2017 – 2019</td>
<td>NHMRC Career Development Fellow</td>
<td>$1,730,869</td>
<td>$138,640</td>
<td>$40,000</td>
</tr>
<tr>
<td>Dr Christopher Williams</td>
<td>2018 – 2020</td>
<td>NHMRC Career Development Fellow</td>
<td>$769,039</td>
<td>$39,024</td>
<td>$20,000</td>
</tr>
</tbody>
</table>

### Career Development Fellows - Category 2

<table>
<thead>
<tr>
<th>Name</th>
<th>Period</th>
<th>Research Area</th>
<th>Grants Submitted</th>
<th>Publications</th>
<th>HDR Supervision</th>
</tr>
</thead>
<tbody>
<tr>
<td>Associate Professor Tracy Burrows</td>
<td>2016 – 2019</td>
<td>Food Addiction</td>
<td>29</td>
<td>219</td>
<td>14</td>
</tr>
<tr>
<td>Dr Susan Hua</td>
<td>2016 – 2019</td>
<td>Nanotechnology</td>
<td>27</td>
<td>32</td>
<td>7</td>
</tr>
<tr>
<td>Dr Natalie Johnson</td>
<td>2016 – 2019</td>
<td>Health Behaviour</td>
<td>9</td>
<td>35</td>
<td>3</td>
</tr>
<tr>
<td>Fellow</td>
<td>Period</td>
<td>Research Group</td>
<td>Project title</td>
<td>Outputs - Grant Funding and Publications</td>
<td>Brawn Fellowship Payments</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-----------------</td>
<td>--------------------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>Associate Professor Simon Keely</td>
<td>2016 – 2019</td>
<td></td>
<td>Digestive disease and infection</td>
<td>32</td>
<td>81</td>
</tr>
<tr>
<td>Dr Yolanda Surjan</td>
<td>2016 – 2019</td>
<td></td>
<td>Radiation Therapy treatment of OSCC/POSCC in horses</td>
<td>38</td>
<td>18</td>
</tr>
<tr>
<td>Dr Amanda Wilson</td>
<td>2016 – 2019</td>
<td></td>
<td>Media Doctor</td>
<td>20</td>
<td>129</td>
</tr>
<tr>
<td>Dr Kirsti Haracz</td>
<td>2017 - 2020</td>
<td></td>
<td>Multimodal program to address lifestyle behaviours associated with obesity and poorer health outcomes for people living with severe mental illnesses (SMI).</td>
<td>10</td>
<td>37</td>
</tr>
<tr>
<td>Dr Liz Holliday</td>
<td>2017 - 2020</td>
<td></td>
<td>Medical Statistics (biostatistics), epidemiology, and genetic epidemiology</td>
<td>32</td>
<td>207</td>
</tr>
<tr>
<td>Associate Professor Jay Horvat</td>
<td>2017 - 2020</td>
<td></td>
<td>Role of iron in respiratory disease</td>
<td>31</td>
<td>149</td>
</tr>
<tr>
<td>Dr Melinda Hutchesson</td>
<td>2017 - 2020</td>
<td></td>
<td>Development, delivery and evaluation of interventions (nutrition and physical activity) for young adults to prevent weight gain and reduce the risk of chronic disease risk factors</td>
<td>28</td>
<td>150</td>
</tr>
<tr>
<td>Dr Janet Wallace</td>
<td>2017 - 2020</td>
<td></td>
<td>Senior Smiles program</td>
<td>20</td>
<td>77</td>
</tr>
</tbody>
</table>

$\text{Post-Doctoral Fellows}$

<table>
<thead>
<tr>
<th>Fellow</th>
<th>Period</th>
<th>Research Group</th>
<th>Project title</th>
<th>Outputs - Grant Funding and Publications</th>
<th>Brawn Fellowship Payments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Liz Holliday</td>
<td>2010</td>
<td>Information Based Medicine</td>
<td>Integrating genome-wide association, gene expression and DNA sequence data to identify risk variants for complex disease</td>
<td>$7,682,676</td>
<td>$75,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>207 Publications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Years</td>
<td>Category</td>
<td>Title</td>
<td>Funding</td>
<td>Publications</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------</td>
<td>---------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Dr Bente Talseth-Palmer</td>
<td>2008-2010</td>
<td>Information Based Medicine</td>
<td>Genetics of Hereditary Nonpolyposis Colorectal Cancer (HNPPCC)</td>
<td>$1,608,112</td>
<td>61</td>
</tr>
<tr>
<td>Dr Larisa Bobrovskaya</td>
<td>2008-2010</td>
<td>Brain and Mental Health</td>
<td>Angiotensin regulation of catecholamine synthesis: a possible role in depression and cardiovascular disease</td>
<td>$77,486</td>
<td>21</td>
</tr>
<tr>
<td>Dr Evan Doran</td>
<td>2008-2010</td>
<td>Gender, Health and Ageing</td>
<td>Pharmaco-epidemiological</td>
<td>$1,550,403</td>
<td>38</td>
</tr>
<tr>
<td>Dr Nikola Bowden</td>
<td>2008</td>
<td>Information Based Medicine</td>
<td>Molecular Mechanisms of UV-light induced malignancies</td>
<td>$4,175,339</td>
<td>139</td>
</tr>
<tr>
<td>Dr Carl Parsons</td>
<td>2005 – 2007</td>
<td>Brain &amp; Mental Health</td>
<td>Brain plasticity in sensory cortex following trauma</td>
<td>$117,171</td>
<td>3</td>
</tr>
<tr>
<td>Dr Eng Cheng Chan</td>
<td>2005</td>
<td>Mothers and Babies</td>
<td>Genomic approaches to identifying the genes that regulate human birth</td>
<td>$92,270</td>
<td>23</td>
</tr>
<tr>
<td>Dr Margaret Wade</td>
<td>2005</td>
<td>Vaccines, Immunity, Viruses &amp; Asthma Research Program</td>
<td>Investigation of the association between chlamydial infection and asthma.</td>
<td>Data not available</td>
<td>16</td>
</tr>
<tr>
<td>Dr Petranel Ferrao</td>
<td>2002 – 2004</td>
<td>Cancer</td>
<td>Mechanisms of drug resistance in acute myeloid leukaemia</td>
<td>Data not available</td>
<td>16</td>
</tr>
<tr>
<td>Dr Geoffrey Partington</td>
<td>2003 – 2004</td>
<td></td>
<td></td>
<td>$210,000</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Years</td>
<td>Department</td>
<td>Research Description</td>
<td>Data Available</td>
<td>Amount</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------</td>
<td>-----------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------------</td>
<td>----------</td>
</tr>
<tr>
<td>Dr Douglas Dorahay</td>
<td>2001–2004</td>
<td>Cancer</td>
<td>Gene mutations in colon cancer enhance tumor progression through MAP kinase signalling</td>
<td>Data not available</td>
<td>$257,000</td>
</tr>
<tr>
<td>Dr Pawel Zarzycki</td>
<td>2000–2002</td>
<td>Mothers and Babies</td>
<td>Chromatographic analysis of steroids in biological fluids during human pregnancy</td>
<td>Data not available</td>
<td>$150,000</td>
</tr>
<tr>
<td>Dr Parveen Rudra</td>
<td>2000–2001</td>
<td>Nutrition and Dietetics</td>
<td>Cell-signalling pathways in n-3 polyunsaturated fatty acid enriched procine myocytes</td>
<td>Data not available</td>
<td>$130,000</td>
</tr>
<tr>
<td>Dr Rick Thorne</td>
<td>2000–2001</td>
<td>Cancer</td>
<td>Interplay between cell adhesion molecules in melanoma</td>
<td>$6,924,433</td>
<td>$135,000</td>
</tr>
<tr>
<td>Dr Martin Cammarota</td>
<td>2000–2001</td>
<td>Neuroscience</td>
<td>Cross-talk between key signalling pathways in model neuronal cells</td>
<td>Data not available</td>
<td>$130,000</td>
</tr>
<tr>
<td>Dr Christopher Katnik</td>
<td>1999–2001</td>
<td>Cardiovascular</td>
<td>Basis for cellular rhythmicity</td>
<td>Data not available</td>
<td>$130,000</td>
</tr>
<tr>
<td>Dr Diane O’Donnell</td>
<td>1998–2000</td>
<td>Clinical Pharmacology</td>
<td>Methodological developments in evidence-based practice and policy</td>
<td>Data not available</td>
<td>$261,000</td>
</tr>
<tr>
<td>Dr Nuzhat Ahmed</td>
<td>1998–2000</td>
<td>Cancer</td>
<td>Integrin-mediated regulation of colon cancer growth</td>
<td>Data not available</td>
<td>$90,000</td>
</tr>
<tr>
<td>Dr Vicki Clifton</td>
<td>1998–2000</td>
<td>Mothers and Babies</td>
<td>Effect of severe asthma on placental function and foetal outcome</td>
<td>$4,637,152</td>
<td>$68,000</td>
</tr>
<tr>
<td>Candidate</td>
<td>Year awarded</td>
<td>Supervisor(s)</td>
<td>Thesis title</td>
<td>Outcome</td>
<td></td>
</tr>
<tr>
<td>---------------------------------</td>
<td>--------------</td>
<td>--------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Ms Susan Reid</td>
<td>2004</td>
<td>A/Professor Darren Rivett</td>
<td>Are sustained natural apophyseal glides an effective treatment for cervicogenic dizziness?</td>
<td>Masters awarded in 2005</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr Robin Callister</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ms Jacqueline Turton</td>
<td>2000</td>
<td>Professor Rodney Scott</td>
<td>Investigating the role of myobacterium avium subspecies paratuberculosis (MAP) in patients with Chron's Disease</td>
<td>PhD awarded in 2012. Student left studies due to illness and then re-enrolled in 2008</td>
<td></td>
</tr>
<tr>
<td>Ms Suvipa Kosumwatcharapoma</td>
<td>2000</td>
<td>Professor Richard Heller</td>
<td>Why has the contraceptive role among Thalassseima couples been low?</td>
<td>Student did not complete studies</td>
<td></td>
</tr>
<tr>
<td>Ms Kelly Cunningham</td>
<td>1999</td>
<td>Dr Darren Shafren</td>
<td>Virus-cell Interactions</td>
<td>PhD awarded in 2003</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Strategic Short-Term Fellowships</th>
<th>Period</th>
<th>Fellowship purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Professor Carolyn Mountford</td>
<td>2011/2012</td>
<td>Salary package support – partially funded for 2 years.</td>
</tr>
<tr>
<td>Professor Eugenie Lumbers</td>
<td>2009</td>
<td>To fund travel costs and incidentals for the Fellow. The Brawn Fund commitment is matched by the Mothers &amp; Babies Research Group.</td>
</tr>
<tr>
<td>(1 year Part-time)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Associate Professor Julie Byles</td>
<td>2000</td>
<td>Fellowship to establish the Hunter Institute of Ageing Research</td>
</tr>
<tr>
<td>(1 year Full-time)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Associate Professor John Rostas</td>
<td>1999</td>
<td>To investigate international models for organising multidisciplinary neuroscience research programs adaptable to Newcastle.</td>
</tr>
<tr>
<td>(9 wks)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Period</td>
<td>Research Group</td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>--------</td>
<td>----------------------</td>
</tr>
<tr>
<td>A/Professor Jessie Berlin, University of Pennsylvania</td>
<td>1999</td>
<td>Systematic Review Group</td>
</tr>
<tr>
<td></td>
<td>3 months</td>
<td></td>
</tr>
</tbody>
</table>
Gladys M Brawn Memorial Fellow Reports

Senior Fellows
Professor Dirk van Helden
Professor Xu Dong Zhang
Professor Amanda Baker
Professor Kypros Kypri
Professor Geoff Isbister
Professor Philip Hansbro
Professor Clare Collins
Professor Frances Kay-Lambkin
Professor Murray Cairns

Career Development Fellows
Professor Billie Bonevski
Dr Chenchen Jiang
Dr Vanessa Murphy
Dr Christopher Williams
Professor Dirk van Helden
Senior Brawn Fellow
Commenced 1998

Primary Research: Cellular Rhythmicity

My laboratory undertakes research in the biomedical sciences investigating cellular rhythmicity, often referred to as pacemaking, in various tissues (e.g. lymphatic, gastrointestinal, uterine, heart and the brain). The grants supporting my present research include a NHMRC supported TACT pilot funding grant and an HMRI Cardiovascular Program grant. I currently co-supervise four PhD students. My research is focussed on several areas including a novel first aid treatment against snakebite and development of my discovery of a new mechanism for cell pacemaking currently applied to pacemaking and signal propagation in the heart. More detailed discussion on some these projects follow.

Through my interest in the lymphatic system, my laboratory discovered a potential first aid treatment against snakebite. The invention involves compounds that when applied topically inhibit the transport of lymph and hence venom transit through the lymphatic pathway. It will be of value especially if used as a co-treatment to the NHMRC recommended method of pressure bandaging with immobilisation. This latter method is the “gold standard” for bites from Australian snakes, reptiles that have venoms that are neurotoxic and haemotoxic. However, research has shown that this is often badly applied in which case it is ineffective only being successful in 15 and 50% of its use when applied by a non-expert and expert respectively. Interestingly, venom also directly enters blood vessels and hence a fully effective chemical first aid will need to inhibit this pathway as well. Our current focus is to investigate mechanisms by which venoms directly enter the vasculature. We are approaching this on the hypothesis that venoms have compounds that increase the permeability of blood vessels. Topical agents that prevent such entry combined with a lymphatic blocker will improve chemical first aid. We have progressed this research establishing a new fluorescent in vivo imaging assay providing evidence that the venom itself causes an increase in vascular permeability. We are now examining ways to inhibit this increase.

The heart pacemaker research has led to the significant finding that a subset of the pacemaker cells generally referred to as “spider” cells are the “starter motor” cells which underlie the initiation of pacemaking. This has broad implications in both health and disease and is the subject of an EOI for NSW state funding offered through the Cardiovascular Research Network.

I am a Co-Leader of the HMRI Cardiovascular Health Program. I am also a member of the Priority Research Centre for Gender, Health and Ageing and the Priority Clinical Centre for Cardiovascular Research. I remain a member on Faculty 1000 and of the Editorial Board of Faculty 1000 Reports. Faculty 1000 is an increasingly important body that assesses quality international research in the field of biomedical sciences.

Publications since 2017 Brawn Report (to date in 2018)


**Invited International Seminars**
A pharmacological approach to snakebite first aid (2017)
Titular de Psicofarmacologia & Neuroetologia, Instituto do Cérebro
Universidade Federal do Rio Grande do Sul, Brazil.
Host: Professor Daniel Gelain

Insights gained from studies on lymphatic pacemaking (2017)
Universidade do Vale do Taquari (Univates)
Host: Dr Ramatis de Oliveira

**Conference Speaker**
Cellular Rhythmicity (2017) Australian Physiological Society Meeting; Melbourne.

**Grants**
Translational Australian Clinical Toxicology (TACT) Program Pilot Grant, NHMRC $18,040.

**2018 PhD Student Co-Supervision**
Ms Kristy Martin
Ms Sonia Tamanna
Amir Ashna
Aysha Ferdoushi
Professor Xu Dong Zhang
Senior Brain Fellow
Commenced 2011

Primary Research: Translational Melanoma

Australia has the highest incidence of melanoma in the world, which is also the most common cancer in young Australians aged 15–39 years old. However, curative treatment of metastatic melanoma remains largely an unaddressed health problem. Although the development of so called “targeted therapy” has achieved unprecedented clinical responses, the benefits are often of limited duration. On the other hand, some novel immunotherapy drugs can result in long-lasting melanoma regression, but only a subset of metastatic melanoma patients benefit from these agents. Therefore, investigations of additional genes and signalling pathways that are deregulated in melanoma and other cancer is a high priority for identification of novel therapeutic targets in the treatment of the disease. This is the major focus of my ongoing research.

During the past year (2017-2018), my research team has consolidated its leading position as a major contributor in the world to understand the mechanism of inappropriate activation of cellular signalling pathways that drive cancer development, progression, and resistance to treatment. My team also established a reputation in understanding of a class of molecules collectively called noncoding RNAs in the pathogenesis of cancer. Besides regular publications in highly ranked journals and presentations in national and international conferences, my research team is also working, in close collaboration with oncologists in turning the information from our laboratory studies into the better personalized management of cancer patients.

In the past year, my research team received 1 NHMRC ($696,162) project grant, 1 HMRI Research Project Grant ($20,000), and 2 Hunter Cancer Research Alliance Pilot Project grant ($30,000). Moreover, I received an University of Newcastle International Engagement Award. My postdoctoral researcher Lei Jin received an Research Excellence Award from the School of Medicine of Public Health and another Research Excellence Award from the Australia Chinese Biomedical Research Association. Two of my PhD students received awards for their presentations in Scientific conferences. Our research was highlighted in the Cancer Council NSW 2018 Annual report.

I continued to serve as a reviewer to assess grant applications for national and international funding bodies including NHMRC, ARC, the Chinese Natural Science Foundation, the Research Council Hong Kong, and Hunter Medical Research Institute (HMRI). I served as an NHMRC Grant Review Panel member and as a reviewer for a large number of highly ranked international journals.

In addition to the administering role as the head of the laboratory, I continued my role as the Deputy Director of the Cancer Research Program of HMRI. I also continued my role as a member of the Research Council of HMRI, a member of the executive committee of the Hunter Translational Cancer Research Alliance, and a member of executive committee of HTCRC. In addition, I was a Co-Director of the Priority Research Centre for Cancer Research, Innovation and Translation.

I have strengthened my collaborations with many medical universities and institutes nationally and internationally, which has led to a number of high quality co-authored publications and presentations. As a representative of the Faculty, I attended the 2017 China Scholarship Council (CSC) Fair. My connections with Chinese universities and institutes have contributed significantly to the establishment of broad collaborations between researchers at the University of Newcastle and those in China. For example, I coordinated visits by
a number of researchers to China, which has resulted in a large collaborative research project that will be largely funded by the partner in China.

During this report period, three PhD students under my supervision have successfully completed their candidature. Moreover, one potential PhD student who will be under my supervision and another two exchange students have received their Australian visas and will join my team by the end of 2018.

Publications since last report


Conference presentations since last report

- **Zhang XD.** Towards eradicating quiescent cancer cells. Symposium of Henan Academy of Medical Science China. Zhengzhou, China, 26th-28th, 2018, Zhengzhou, China (Invited speaker)
- Feng YC, Jin L, Zhang XD. The pan-cancer oncogenic upregulation of the long noncoding RNA5. The 12th Australian Association of Chinese Biomedical Scientists (AACBS) Annual Scientific Meeting, 28th Oct, 2018. Sydney, Australia. (Best Oral Presentation Award)

Grants received since last report

- **Xu Dong Zhang,** Rodney Scott, Tao Liu. Role of lncRNA IDH1-AS1 in regulating c-Myc driven-glycolysis and tumorigenesis. NHMRC Project Grant, $696,162, 2018-2020, NHMRC.
The poor physical health of people with severe mental health problems, such as schizophrenia, bipolar disorder and major depression, is second only to that of Indigenous people in Australia. People who experience disorders such as schizophrenia and bipolar disorder die of non-communicable diseases such as cardiovascular disease and cancer 20 years earlier than Australians without these mental disorders. Quality of life associated with chronic health problems and low socioeconomic status is also significantly lower. Poor quality of life and early mortality are associated with high rates of smoking, alcohol consumption, poor diet and low levels of physical activity.

The major focus of my research is on multiple health behaviour change among people with severe mental health problems. In the last few years I have extended my focus from addressing co-existing mental health and substance use problems (including smoking and alcohol consumption) to also focusing on diet and activity levels. Research among people without a history of mental health treatment has shown that multiple health behaviour change is possible. I am developing interventions that target multiple health behaviours among people with severe mental disorders, being the first internationally to address substance use, diet and activity together.

I am a clinical psychologist who has worked in multidisciplinary clinical and research settings, and I aim to further develop collaborations with others (clinical psychologists, dieticians, exercise physiologists) in Australia and overseas in order to develop and evaluate effective interventions among this challenging group. I am currently on my fourth NHMRC Research Fellowship. These fellowships are highly competitive and awarded to researchers considered to be within the top 10% internationally in their field. My randomised controlled trials have been highly cited and treatments have been widely disseminated.

Key Achievements
In the last year, my key achievements have been:

1. Success on 1 NHMRC Project Grant as CIA, 1 NHMRC Senior Research Fellowship, total value: $1.9M.
2. Election to Fellowship of the Australian Academy of Health and Medical Sciences (FAHMS) for contribution made to health and medical research in Australia.

PRC Membership
Priority Research Centre for Cancer (80%) and Priority Research Centre for Health Behaviour (20%)
Awards
1. Winner, 2018 NADA AOD Awards. Awarded to SMART Recovery Australia Research Advisory Committee (which I chair) for excellence in research and evaluation.
2. Winner, 2017 Outstanding Academic Mentor Award, Division of Psychological Research, Education and Training (DPRET) of the Australian Psychological Society (APS).

Community Contributions

2018 - Consultant, NIMH Research to Inform Stepped-Care Interventions for Persons at Clinical High Risk for Psychosis project.

2017 - Clinical mentoring advice provided by phone to general practitioners and primary care practice nurses within the Hunter New England and Central Coast Local Health Districts. Topics include drug and alcohol (and comorbid mental health problems) screening, brief intervention and referral. Drug and Alcohol Treatment Capacity Building Program, Hunter New England and Central Coast Primary Health Network (PHN), University of Newcastle and Hunter Primary Care, October-December 2017

HDR Supervision
I am currently the primary supervisor of 7 PhD candidates and 1 MClinPsychology students, and co-supervisor for 3 PhD candidates and 1 MClinPsychology student.

2017/2018 Completions: 3 PhD, 1 MClinPsychology

Grants as Chief Investigator (Since last report)
- 2018-2022 Baker, A. ‘Equally Well’: Addressing Comorbid Physical, Mental, and Substance Use Disorders with Psychological Interventions. NHMRC Senior Research Fellowship (including Translation Advancement Incentive Award $10,000 per annum) APP1135901. $715,210

Publications (since last report)
Journal Articles (Students’ names in italics)


**Book Chapters**


**Book Reviews**

Conference Presentations


Professor Kypros Kypri
Senior Brwn Fellow
Commenced 2013

Research Area: Epidemiology and prevention of alcohol-related injury and disease

I am a behavioural scientist interested in patterns of harm due to alcohol consumption, and the evaluation of policies and interventions to reduce alcohol-related morbidity and mortality. I am nearing the end of the final year of a National Health and Medical Research Council Senior Fellowship. I have established an alcohol research group at the University of Newcastle that is the hub of several national and international collaborative studies. I have a longstanding interest in research translation and have been active in encouraging the systematic use of science in the development of public policy, particularly in relation to the regulation of the night-time economy and the availability and promotion of alcohol. Increasingly my focus is on barriers to research translation, in particularly alcohol industry activity to thwart effective public policy, and how governments procure, evaluate, and utilise scientific evidence in policy development. I am a senior member of the PRC in Health Behaviour.

Research activities since 1 October 2017: My group has had success in each of my programme’s research streams: (1) Epidemiology of risky drinking, alcohol use disorder, and other addictive behaviour, (2) Evaluation of interventions, and (3) Barriers to translation.

Key achievements
- The commencement of two major competitive grant funded projects (details below)
- Publication of a peer-reviewed article in the BMJ, one of the “Big 4” general medical journals
- Two student PhD submissions in critically important areas of public health, namely Indigenous alcohol-related harm, and parental behaviour as determinants of adolescent drinking
- Appointment as scientific advisor to the End Alcohol Advertising In Sport campaign

Publications
I published papers in leading medical, public health, and substance use journals, with findings directly relevant to current policy debate in Australia and other countries.

Stream 1: Epidemiology of risky drinking, alcohol use disorder, and other addictive behaviour

Stream 2: Evaluation of interventions

Stream 3: Barriers to translation
10. Robertson N, Kypri K, Stafford J et al (2018). Australian lobbyist registers are not serving the purposes they were designed for. Drug and Alcohol Review 37 Suppl 1:S218-S222

Major projects commenced
After grant success in the previous reporting period, I have spent much of the last 12 months establishing new research, including the recruitment of staff and PhD students, for these two projects in particular:


Competitive funding awarded
Baker et al. Pilot randomised controlled trial of a telephone delivered intervention for hazardous alcohol use among young people living with severe mental ill-health, 2018, Australian Rotary Health $67,653

Research Higher Degree students
PhD submissions currently under examination:
Doctor of Philosophy thesis, Co-supervisor – Peter Malouf, James Cook University, from 2015: Alcohol consumption and related harm among indigenous Australian university students. (Submitted March 2018; received largely positive reviews from examiners, requiring relatively minor changes.)

Doctor of Philosophy (Community Medicine & Clinical Epidemiology) thesis, Primary supervisor – Sonia Sharmin, University of Newcastle, from September 2014): Parental supply of alcohol and adolescent risky drinking (Submitted 6 October 2018)
Translation
I became scientific advisor to the End Alcohol Advertising In Sport campaign (October 2018) www.endalcoholadvertisinginsport.org.au
I continued as Chair of the Australian Health Policy Collaboration Working Group on Alcohol to assess Australia’s progress against the WHO 25 x 25 targets.
I continued in my role on the Executive Committee of the National Alcohol Action Alliance, and have been active in advocating for the adoption of an evidence-based National Alcohol Strategy 2018.
I served on the Scientific Programme Committee, for the Annual Symposium of the Kettil Bruun Society for Social & Epidemiological Research on Alcohol, Chang Mai, May-June 2018.
My research has been covered in global (BBC, The Guardian, Washington Post), national (ABC, SMH/Age, News.com), and local news media (Newcastle Herald, local radio), on subjects including effects of parent supply of alcohol to children, alcohol outlet trading hours, and industry influence on policy decisions.
(See: https://www.google.com.au/search?q=kypros+kypri&source=lnms&tbm=nws&sa=X&ved=0ahUKEwiup_vX_tzdAhUDbbwKHdq3B8cQ_AUIECgD&biw=1680&bih=917)

Invited presentations
Designing alcohol policy research, Centre for Alcohol Studies and Thai Health Promotion Foundation Bangkok, Thailand, 14 February 2018
Peculiar differences in Australian and New Zealand beer markets. Institute for Psychotherapy - Munich. Munich, Germany, 4 June 2018
Alcohol industry use of science and scientists for policy outcomes: Breaking the chains of engagement. Foundation for Alcohol Research and Education, Canberra, 11 September 2018
Professor Geoff Isbister
Senior Brawn Fellow
Commenced 2014

Research Area: Clinical Toxicology

I lead the Clinical Toxicology Research Group at the University of Newcastle, which is also a sub-group of the HMRI Cardiovascular Health Program. The group includes five staff including research administration and laboratory staff and five PhD students. I also supervise 4 other PhD students off-site, one MPhil and two PhDs in Sri Lanka (University of Peradeniya). Ongoing major areas of research include: studies into the efficacy and effectiveness of treatments for envenomed patients, multicentre research into the effects of drugs in overdose, research into the effects of drugs on the heart, specifically those associated with fatal arrhythmias and development of risk assessment tools. I also undertake research in emergency medicine, principally on sedating aggressive patients.

I am principal investigator on a number of observational and interventional studies on snake envenoming, including the Australian Snakebite Project (ASP) and studies in Sri Lanka on snake bite. ASP has changed the treatment of snake bite in Australia and the way that antivenom is used. Last year we published 10 years of snakebite in Australia. ASP continues to investigate other treatments for snake bite, including early antivenom, acute kidney injury, phospholipase A2 assays and interventions for myotoxicity. It is funded by an NHMRC Centre for Research Excellence. I have undertaken two randomised controls of fresh frozen plasma in snakebite coagulopathy, one in Australia and one in Sri Lanka. In November 2015 I was the CIA on a successful NHMRC Centre for Research Excellence – Translational Venom and Antivenom CRE. This year I published an editorial in the Lancet on the challenges to snakebite treatment globally.

I continue work on the treatment of redback spider bite following the Redback Spider Antivenom Evaluation (RAVE II) Study that found antivenom did not improve outcomes in redback spider bites. This was a controversial finding that challenges the current use of antivenom and was featured on Catalyst in February 2015. We are now focussing on novel analgesics for the pain of redback spider bite, including ketamine, clonidine and pregabalin.

I am the principal investigator on a long term ongoing multicentre project investigating the time course and effects of drugs in overdose, using patient blood samples and clinical data. This is a collaboration with Prof Stephen Duffull at the University of Otago. The study aims to develop clinical guidelines for treatment using novel drug modelling techniques. These studies have rationalised the treatment for particular drug overdoses, streamlining the care of patients. This includes research into the effects of drugs on the heart and associated fatal heart arrhythmias. My research group has also developed a risk assessment tool (QT nomogram) that is a more accurate measurement technique for detecting an abnormal heart rhythm in patients. This year I published an editorial in the Medical Journal of Australia on research and data collection from the National Poison Centre Network.

Other current projects include prospective studies of overdose patients with NHMRC Program Grant funding. This has become the Australian Toxicology Monitoring (ATOM) study and includes studies on paracetamol, digoxin, beta-blockers, metformin, valproate and anticoagulants. In addition, we have reported a number of single cases of novel and new drugs and chemicals causing human poisoning, including chloroform and levetiracetam poisoning. The funding also supports the Hunter Area Toxicology
Service database which is a large cohort of poisoned patients used to investigate the toxicity of drugs in overdose. This continues as a collaboration with the University of Sydney and the NSW Poison Centre. I became a Senior Editor of the British Journal of Clinical Pharmacology in September 2015 and have played an active role in the ongoing development of the journal, including producing an issue on Therapeutics in Clinical Toxicology in March 2016. I am also an Associate Editor for PLoS Neglected Tropical Diseases.

**Refereed Journal Articles**


**Reviews**


**Editorials/Letters**


**Invited Seminars**

1. Royal Prince Alfred Grand Rounds; Australian Snakebite.
2. International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) Congress September 2018. Plenary presentation ‘Clinical Toxicology – evidence to address the myths’

**Current Grants**

- **NHMRC Senior Research Fellowship (B).** “Multicentre studies of interventions in clinical toxicology and envenoming, including antivenoms, antidotes and decontamination” Isbister G. $739,515
• **NHMRC Program Grant:** “An integrated research program in human toxicology to ensure rapid translation of results into practice and regulation.” Buckley NA, Isbister GK, Dawson A, Roberts M. 2014-2018. $6,846,800


**Awards**

**Higher Degree Research Graduates**
Primary Supervisor: primary supervisor for 10 current PhD candidates and one MPhil.
**Professor Philip Hansbro**  
Senior Brawn Fellow  
Commenced 2015

**Research Area:** Respiratory diseases particularly asthma, chronic obstructive pulmonary disease, infections and lung cancer. Also Chlamydia STDs.

Professor Hansbro has established research programs in 3 fields; COPD, asthma and infection, and is developing a 4th in lung cancer. To do this he has developed “world first” mouse models of these complex diseases (e.g. COPD, severe steroid-resistant asthma, early life infection, lung cancer). He has interrogated them (immune, histological, pathological & molecular analysis, lung function) to substantially further our understanding of the pathogenesis of these currently untreatable diseases. This has led to the identification and development of novel potential therapeutic approaches. He performs complimentary clinical studies, collaborates widely with other high profile scientists nationally and internationally, and has a long track record of mentoring junior researchers.

Core member of the PRCs for Healthy Lungs and the Gut, and Vaccines, infection/immunity, viruses and asthma (VIVA) group of HMRI.

**Key Achievements that have led to the identification of new therapeutic targets and treatments**

1. Identified that the age, timing and nature of infection is critical in determining effects on asthma.  
2. Determined that respiratory bacterial and viral infections induces severe asthma in early life and adults, through the induction of PI3K, microRNAs and IL-13.  
3. Showed that combination of respiratory infections and asthma drives a severe steroid-resistant asthma phenotype and chronic infection in adults.  
4. Showed that *Streptococcus pneumoniae* exposure is protective against asthma.  
5. Identified potential novel asthma therapeutic strategies that either target or utilise bacteria.  
6. Created short-term mouse models of cigarette smoke-induced COPD and lung cancer, which have the major features of the human disease, and showing important roles for the microbiome, epigenetics & metabolism.  
7. Identified novel roles for mast cell tryptases in experimental COPD.  
9. Discovered that a new interferon, IFN, protects against *Chlamydia* reproductive tract infection.  
10. Established a nationwide surveillance program for avian influenza & undertakes all the NSW surveillance.

**Measures of output (i.e. publications, grants, HDR supervision, major prizes)**

**Standing:** High-level record of achievement & performance as a research leader recognised by accelerated promotion (Lecturer in 2005 to Professor in 2011, Professor E+ 2014), and high-level appointments (Deputy director of CARD & the CRC for Asthma & Airways [CRCAA, UoN 2005-12], Head, Discipline of Immunology & Microbiology [2007-11], joint leader of Infection & Immunity Research Cluster, Director of School Research Committee). These Centres & Groups are internationally recognised for contributions to respiratory & infectious diseases. On the Boards and is Chair of Research Committees of Thoracic Society of Australia/NZ and the Faculty of Health and Medicine, University of Newcastle. Awarded NHMRC Principal Research Fellowship 2015-19. Inducted as a Fellow of Thoracic Society of Australia & New Zealand 2017.

Grants: Since 2010 as CIA awarded/held 10xNHMRC & 2xARC project grants, as CIB/C 4xNHMRC. NHMRC PRF 2015-19. Many industry consultancies (see Table below).

Supervision & mentoring: Total 34 graduated PhD students 16 as primary, 22 ongoing 14 as primary. Since 2013 graduated 24 PhDs (+2 submitted): 14 PhD students as primary, 2 UoN alumni of the year 2014 & 2017 & other finalist 2016, 2017, 10 as co-supervisor (+2 submitted), 1 Masters completed 2013. Total 26 graduated honours students 15 as primary, in last 5 yrs 5 as primary (2 won University medal), 2 as co-supervisor – all bar one 1st class. All PhD graduates have excellent subsequent positions as Post-docs, or junior academics. Mentored four junior staff, 3 now have tenure and 3 were awarded new investigator grants or NHMRC/ARC Fellowships, 2011-16.

Publications (since last report):

2017 (39)


166. Leung JM, Tiew PY, Mac Aogain M, Budden KF, Yong VF, Thomas SS, Pethe K, Hansbro PM, Chotirmall SH. The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD. Respiratory 201722(4):634-50 (IF = 3.495, ERA = B).


2018 (39)


212. Wood LG, Li Q, Scott HA, Ruttin S, Berthon BS, Gibson PG, Hansbro PM, Williams E, Horvat J, Simpson JL, Young P, Oliver BG, Baines KJ. Saturated fatty acids, obesity and the NLRP3 inflammasome in asthma. *Journal of Allergy and Clinical Immunology* in press accepted 1.5.18


218. Nixon B, Johnston S, Skerrett-Byrne D, Anderson A, Stanger S, Bromfield E, Martin J, Hansbro PM, Dun M. Proteomic profiling of crocodile spermatozoa refutes the tenet that post-testicular maturation is restricted to mammals. *Molecular and Cellular Proteomics* accepted 3.8.18 (IF 5.232)


224. Rutting S, Papanicolaou M, Xenaki D, Wood LG, Mullin A, Hansbro PM, Oliver BG. Dietary ω-6 polyunsaturated fatty acid arachidonic acid increases inflammation, but inhibits ECM protein expression in COPD. *Respiratory Research* accepted 22.10.18


Grants (since last report):

<table>
<thead>
<tr>
<th>Research Team</th>
<th>Project Description</th>
<th>Year(s)</th>
<th>Amount</th>
<th>Funding Body</th>
<th>Grant Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hansbro, Wark, Horvat, Hurt</td>
<td>Defining the roles and targeting interferon-epsilon as a new therapy for influenza in asthma and COPD #1138004</td>
<td>2018-22</td>
<td>905,904</td>
<td>NHMRC</td>
<td>Project grant</td>
</tr>
<tr>
<td>Hansbro, Wark, Adcock, Miyake</td>
<td>Elucidating the role and potential for therapeutic targeting of TLR7 in emphysema and COPD #1137995</td>
<td>2018-22</td>
<td>925,780</td>
<td>NHMRC</td>
<td>Project grant</td>
</tr>
<tr>
<td>Hansbro, Rahman</td>
<td>Developing treatments for lung cancer</td>
<td>2018-19</td>
<td>250,00 USD</td>
<td>Int Assoc Study Lung Cancer</td>
<td>Fellowship support</td>
</tr>
<tr>
<td>Hansbro, Wark, Whiteman, Adcock</td>
<td>Developing new treatments for lung cancer # APP1156589</td>
<td>2019-2022</td>
<td>880,000</td>
<td>NHMRC</td>
<td>Project grant</td>
</tr>
</tbody>
</table>
Professor Clare Collins
Senior Brawn Fellow
Commenced 2016

Research Area: Medical nutrition therapy to improve diet related health outcomes: Evidence, Interventions and Translation (FoR1111 Nutrition and Dietetics)

Poor diet accounts for the greatest burden of disease in Australia and internationally. My research is developing novel, technology based methods to individually tailor nutrition advice, provide personalised feedback and give health professionals access to nutrition tools and data in real-time, that they can use to help people eat better. It has not been possible to do this before as we did not have the technological capacity to provide feedback in a temporal and efficient way. Enabling technologies mean that - now we do!

I am seeking to transform the field of personalised medical nutrition therapy. My vision is to evaluate novel, targeted and tailored approaches that translate nutrition evidence into practical strategies to improve nutritional status. I am bridging the evidence-to-action gap using tailored technology components to motivate and support people to optimise eating patterns and diet quality. This will address equity, improve quality of life while reducing diet-related morbidity, mortality and health costs.

I am extending my interdisciplinary leadership and national and international collaborations with health professionals, health sector, government and industry to evaluate nutrition assessment technology at specific life stages and chronic conditions, such as diabetes and cardiovascular disease. In addition I have increased my mentoring and support of early and mid-career researchers both within and outside my discipline. I have continued to ensure I have a strong voice in public communication of nutrition science and see this as making a valuable impact in terms of research translation.

I am the Director of Research School of Health Sciences; Deputy Director PRC in Physical Activity and Nutrition; HMRI CVD group

Key Achievements Since September 2017 (Note My Brawn Fellowship commenced in January 2016.)

Major Awards
2017 Hunter Medical Research Institute, Researcher of the Year
2018 Dietitians Association of Australia (DAA) President’s Award for Innovation in Honour of the Memory of Josephine Rogers.
Measures of output since September 2017
Grants – Total >$4.5 million

<table>
<thead>
<tr>
<th>Grant Period</th>
<th>Granting Body</th>
<th>Chief Investigators</th>
<th>Title</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>National Heart Foundation of Australia</td>
<td>Hutchesson, Collins, Callister, Park</td>
<td>A targeted eHealth intervention to reduce CVD risk among women with a history of pre-eclampsia</td>
<td>$74,892</td>
</tr>
<tr>
<td>2018-2020</td>
<td>nib Foundation</td>
<td>Collins, Burrows, Rollo, Adam</td>
<td>Personalised nutrition assessment and advice to motivate and support young Australians in improving their diet related health and wellbeing</td>
<td>$893,750</td>
</tr>
<tr>
<td>2017-2019</td>
<td>Bill &amp; Melinda Gates Foundation OPP1171389</td>
<td>Rollo, Burrows Collins, Adam, Smith</td>
<td>Using voice, images and sensors to measure individual food and nutrient intake: development and evaluation of the VISIDA system</td>
<td>$1,654,526 ($US 1,313,190)</td>
</tr>
<tr>
<td>2017</td>
<td>HMRI G1700553 nib Foundation</td>
<td>Collins, Burrows</td>
<td>Nutrition Connect: Online Platform to link rural families to health professionals for healthy eating</td>
<td>$42974</td>
</tr>
<tr>
<td>2017-2018</td>
<td>Heart Foundation, NSW CVRN Office for Health &amp; Medical</td>
<td>Duncan, Glozier, Plotnikoff, Kolt, Holliday, McEvoy, Hensley, Collins, Brown Morgan, Vandelanotte,</td>
<td>Improving understanding of sleep, physical activity, diet as CVD risk factors</td>
<td>$190609</td>
</tr>
<tr>
<td>2017</td>
<td>DARP</td>
<td>Collins, Callister, Rollo, Hutchesson Aguiar, Wynne, Young</td>
<td>Evaluation of a type 2 diabetes risk reduction program for women with recent gestational diabetes</td>
<td>$59911</td>
</tr>
<tr>
<td>2017</td>
<td>DARP</td>
<td>Duncan, Plotnikoff, Collins, Morgan, Vandelanotte, Brown</td>
<td>Sleep, Move &amp; Eat: An RCT testing novel strategies to improve efficacy of behavioural weight loss interventions</td>
<td>$59808</td>
</tr>
<tr>
<td>2017</td>
<td>HMRI (Rainbow Foundation)</td>
<td>Collins Burrow Hutchesson</td>
<td>Nutrition and Dietetics</td>
<td>$60 000</td>
</tr>
<tr>
<td>2017-2019</td>
<td>Greater Charitable Foundation</td>
<td>Morgan, Young, Barnes, Collins, Pollock</td>
<td>Healthy Youngers, Healthy Dads</td>
<td>$349,947</td>
</tr>
<tr>
<td>2017 – 2019</td>
<td>HMRI G1701279</td>
<td>Young, Morgan, Kay-Lambkin, Collins, Callister, Kelly</td>
<td>SHED-IT Recharge: Development and evaluation of a gender-tailored program designed to improve men’s physical and mental health</td>
<td>$142,500</td>
</tr>
<tr>
<td>2017</td>
<td>HMRI G1700567</td>
<td>Rollo, Collins, Callister, Wynne, Hutchesson, Aguiar</td>
<td>Demand, acceptability and preliminary efficacy of a type 2 diabetes risk reduction program for women with recent gestational diabetes</td>
<td></td>
</tr>
<tr>
<td>2017</td>
<td>University of Newcastle</td>
<td>Schumacher, Brown, May, Collins, Boyle</td>
<td>Feasibility and engagement strategies for a cardiovascular disease prevention program targeting a high need, low health literacy rural community.</td>
<td></td>
</tr>
<tr>
<td>2017-2020</td>
<td>NHMRC APP1128317</td>
<td>Baur, Truby, Garnett, Varady, Cowell, Collins, Paxton, Lister, Gow</td>
<td>The alternate day fasting diet in adolescents with obesity: a randomised controlled trial</td>
<td>$1,007,545</td>
</tr>
</tbody>
</table>

HDR supervision
PhD Candidates (Awarded or submitted since Sept 2017 to date)

**Principle Supervisor (Nutrition & Dietetics)**

1. **2013-2017** Lee Ashton (F/T 30%) (International) The HEYMAN Study: A Nutrition Intervention Using Information Technology in Young Males: Feasibility and Effectiveness

**Co-Supervisor**

3. **2012- 2017** Rebecca Williams (Biomedical Sciences) (20%) Gender and Hormonal Regulation of Body Weight During Weight Loss Programs


5. **2014- Submitted** Rachel Taylor (F/T 20%) Nutrition and cognition in children (under examination).

**Supervised projects receiving awards (note, this is not a complete list)**

1. 2018 Ms Hannah Brown University of Newcastle 3-Minute Thesis Faculty of Health and medicine and UON overall winner and UON representative in the Asia-Pacific 3MT finals


3. 2018 Dr Lee Ashton, selected competitively to to participate in the 68th Lindau Nobel Laureate Meeting dedicated to Physiology and Medicine (2018)

4. 2018 Dr Rebecca Haslam (nee Williams) Dr Dave Roberts Memorial Award in Food and Nutritional Science. Awarded based on high academic merit to a Post-Doctoral Fellow in Nutrition and Dietetics; supported by International Life Sciences Institute SEA Region A’Asia

5. 2017 Dr Lee Ashton ISBNPA award for Best Student oral presentation International Society for Behavioral Nutrition and Physical Activity Conference


**Publications**

**Report**


**Innovative works**

Massive Online Open Course (MOOC); the Science of Weight Loss – Dispelling Diet Myths, Version 2 launched 31/1/18, >10000 enrolled from >160 countries https://www.edx.org/course/science-weight-loss-dispelling-diet-newcastlex-sw101x

**Science Media Translation and Communication**

The Conversation, 17 articles
Invited Regular Guest on TripleJ Science Hour with Dr Karl and Linda; ShirtLoads of Science podcasts
Fortnightly Interviews on 2NUR and frequent media interviews

**InvitedOnline Articles For The Conversation**


2. **Do vitamin supplements prevent macular degeneration?** The Conversation 31st October 2017; >6226 readers, 0 Comments, 28 Tweets, 127 Facebook Shares https://theconversation.com/do-vitamin-supplements-prevent-macular-degeneration-86519

3. **Research Check: will a coffee a day really keep heart attacks at bay?** The Conversation 21st November 2017; >49982 readers, 91 Comments, 44 Tweets, 467 Facebook Shares


6. Five supplements that claim to speed up weight loss – and what the science says The Conversation 30th January 2018; >366,000 readers, 34 Comments, 56 Tweets, 393 Facebook Shares https://theconversation.com/five-supplements-that-claim-to-speed-up-weight-loss-and-what-the-science-says-89856


8. Interview: We asked five experts: should I let my kids drink juice? The Conversation 13th March 2018; >100708 readers, 74 Comments, 83 Tweets, 459 Facebook Shares https://theconversation.com/we-asked-five-experts-should-i-let-my-kids-drink-juice-92176

9. Research Check: is it true pasta doesn’t make you gain weight, and could even help you lose it? The Conversation April 12th 2018; >55918 readers, 47 Comments, 31 Tweets, 334 Facebook Shares https://theconversation.com/research-check-is-it-true-pasta-doesnt-make-you-gain-weight-and-could-even-help-you-lose-it-94570

10. New vitamin supplement study finds they may do more harm than good. The Conversation May 29th 2018; >167017 readers, 149 Comments, 104 Tweets, 1600 Facebook Shares https://theconversation.com/new-vitamin-supplement-study-finds-they-may-do-more-harm-than-good-97246


15. We asked five experts: is cheese bad for you? The Conversation 24th July 2018; >146,454 readers, 206 Comments, 95 Tweets, 1554 Facebook Shares https://theconversation.com/we-asked-five-experts-is-cheese-bad-for-you-98156

16. Health Check: should I take vitamin C or other supplements for my cold? The Conversation 6th August 2018; >77192 readers, 29 Comments, 31 Tweets, 490 Facebook Shares https://theconversation.com/health-check-should-i-take-vitamin-c-or-other-supplements-for-my-cold-98309


Peer Reviewed Journal Articles Accepted/Published since Sept 2017 (Current Scopus H-Index = 46)

2. Vincze L, Rollo M, Hutchesson M, Hauck Y, MacDonald-Wicks L, Wood L, Callister R, Collins CE. Interventions including a nutrition component aimed at managing gestational weight gain or postpartum weight retention: a systematic review and meta-analysis. BISRIR-2017-003593R2 Accepted The Joanna Briggs Institute Database of Systematic Reviews and Implementation Reports. 31st August 2018


9. Holmes K-L, Collins CE, Rollo ME. Do the contemporary dietary patterns of children align with national food and nutrient recommendations? Submitted to JHND November 2017 comments received Dec 23rd 2017- Resubmitted 18th Feb JHND-17-11-0398-OR Accepted May 4th 2018


23. Schumacher T, Weatherall L, Keogh L, Sutherland K, Collins CE, Pringle KG, Rae KM. Characterizing gestational weight gain in a cohort of Australian Indigenous women. Accepted in Midwifery, 26th Jan 2018


29. Rachael Taylor; Shanna Fealy; Alessandra Bisquera; Roger Smith; Collins CE; Tiffany-Jane Evans; Alexis Hure. Effects of nutritional interventions during pregnancy on infant and child cognitive outcomes: a systematic review and meta-analysis. Nutrients 2017, 9(11), 1265; doi:10.3390/nu9111265


Editorial responsibilities for Scientific Journal Boards
2018 Guest Editor Special Issue NUTRIENTS. Portion Size Education. Editors: Tamara Bucher, Megan Rollo, Tracey McCaffrey, Ingrid Steenhaus, Clare Collins. Closes October 30th 2018
Invited Conference and Seminar Presentations

International
1. 2018 International Society for Behavioral Nutrition and Physical Activity (ISBNPA), Invited presenter in ECR workshop; COMMUNICATING RESEARCH WITH IMPACT;... think outside the bowl
2. 2018 International Society for Behavioral Nutrition and Physical Activity (ISBNPA), Invited presenter for e&mHealth Interest Group; How to PITCH your research.
3. 2018 International Society for Behavioral Nutrition and Physical Activity (ISBNPA), Invited presenter in Symposium on research related to Food Preparation & Cooking skills, diet quality and health (Hong Kong) June 2018, with Prof M Dean (Ireland), Dr J Wolfson (USA), Dr F Lavelle (Ireland), Dr T Bucher (Aust)
4. 2018 ISBNPA, Invited Chair of Symposium on Interventions Targeting Young Adults
5. 2018 12th Australasian Cleft Lip & Palate Association Conference 3rd May, Sydney, Childhood Obesity; Feeding children to improve their nutrition-related health and prevent obesity

National
6. 2018 Australasian Lifestyle Medicine Conference, 18th August Brisbane Using Technology To Deliver Personalised Nutrition Advice
7. 2018 Hemochromatosis Australia, August 25th Newcastle Hereditary haemochromatosis: A cautionary tale of dietary iron, nutrition and supplements
8. 2018 Dietitian’s Association of Australia Pre-conference workshop 16th May Sydney; Assessing your fellowship application

Regional
9. NSW Rural Research Program (Webinar) 1st May; From clinical practice to research - From little things big things grow
People with mental illness lose 1 day of life in every 4 compared to the general population, not due to mental illness, but to the same lifestyle mediated chronic health conditions that affect the general population. This gap in life expectancy is worse than for other disadvantaged groups, including Indigenous populations. Efforts to reduce excess mortality in mental illness have largely focussed on prevention and risk reduction for suicide and related issues. Whilst important in reducing the excess non-accidental mortality in mental illness, comparatively little attention has been paid to reducing the risk of physical conditions, which account for 80% of excess deaths. Tobacco, alcohol misuse, illicit drug use, physical inactivity, poor nutrition and sleep-wake disturbance are the key risk factors for physical health problems, and are disproportionately higher in mental health populations than in the general population. These areas have traditionally been approached in isolation, or not at all, meaning virtually no inroads have been made towards ‘closing the gap’ for people with mental and physical health comorbidities.

These risk factors are compounded by a significant level of unmet need for mental health treatment. Despite an annual investment in mental health of $4.2 billion, fewer than 1/4 of people access treatment. eHealth interventions have the potential to increase mental health treatment access and deliver interventions that integrate mental health with the key risk factors for physical health problems.

My vision is to build a highly innovative program of eHealth interventions for mental health populations, which address the key risk factors for physical health comorbidities. It is my aim to bring high quality, evidence based treatment to the point-of-care for people experiencing mental health and addictive disorders to ensure that the right person receives the right intervention at the right time.

I am the Deputy Director, Mental Health Hub, Priority Research Centre for Brain and Mental Health

Member of the Brain and Mental Health Program, Hunter Medical Research Institute

AIMS (Figure 1)
The broad goal of my research program is to develop high quality, evidence-based care that is accessible and acceptable to people with mental and physical health comorbidities. My research program bridges the evidence-practice gap in four key ways: (1) Determining ‘what’ to disseminate; (2) Deciding ‘who’ to disseminate it to; (3) Deciding ‘how’ to disseminate it; and (4) Determining ‘when’ is best to disseminate it.
Key Achievements (2017-2018)
1. Invited international presentation at the World Psychiatric Congress (Melbourne), invited national keynotes at the La Trobe University (Melbourne), and one international research presentation, Society for Behavioral Medicine (New York, USA).
2. Appointed to the Advisory Panel for the Million Minds Mission for the Medical Research Futures Fund.
3. Awarded the 2018 Vice Chancellor’s Award for Research Supervision Excellence.
4. Submission of 2 NHMRC project grants as CIA. Awarded 1 NHMRC project grant as CID to commence in 2018.
5. Submission of 1 NHMRC partnership grant application as CIA, with $150,000 support from BeyondBlue. Outcome unknown.
7. Submission of 1 NHMRC Centre for Research Excellence application as CID. Awarded, to commence in 2018.
8. Submission of 1 Expression of Interest to the Suicide Prevention Research Fund as CIA. One of 9 (out of 52 applications) selected to provide a second stage application. Outcome unknown.
9. Awarded $426,728 to further develop and evaluate the Families and Friends Support Program for people supporting a loved one using crystal methamphetamine.
10. Awarded $485,087 to develop and evaluate a new online program for families and friends supporting a loved one using alcohol/other drugs.
12. Established a new research collaboration with Telethon Kids, to examine the alcohol risk behaviours in University students, commencing 2018.
13. Established the Callaghan Community Drug Action Team at the University of Newcastle to develop strategies to reduce risk associated with alcohol/other drug use amongst this community. Appointed as Chair of the Team, commencing 2018.
14. Appointed as the President for the Society for Mental Health Research, the peak Australian and New Zealand body representing mental health, psychiatric, psychological research).
15. Appointed as Associate Editor, Journal of Clinical Medicine (journal).
16. Attracted 5 new PhD students, commencing in 2018, four with competitive scholarships (Australian Rotary Health, Suicide Prevention Research Fund, Defence Health Scholarship, Everymind PhD Scholarship).
17. Developed new online intervention: vSHADE for ex-serving Defence Force personnel with mood and alcohol use problems.

- Invited Speaker, Ice in our Community. HMRI-sponsored RUOK day breakfast, Hunter Water.
- Invited Speaker, The eCiPSE Project: Integrating low-intensity interventions into the management of comorbid mental health and alcohol/other drug use problems. Webinar with PHNs (Primary Healthcare Networks).
- Invited Speaker, What is this ‘mindfulness’ that everyone is talking about?! Hunter Medical Research Institutem RUOK day breakfast, Hunter Water.
- Panellist, How to support families and friends with a loved one using methamphetamine. An introduction to the Checkmate support package. Panellist, CRE in Mental Health and Substance Use (CREMS) Webinar.
- Invited Speaker, Integration eHealth tools into the treatment of mental health and alcohol/other drug use problems, Drug and Alcohol Clinical Services Education Committee, Sydney.
- Invited Speaker, Bipolar Disorder and Substance Use, Psychosis and Substance Use seminar, Sydney.
- Invited Speaker, The eCiPSE Project: Integrating technology into the management of comorbid mental health and alcohol/other drug use problems, NSW Health QIT (Quality in Treatment) Presentation, Sydney.
Boards and Committees

- Member, Paternal Perinatal Depression Initiative, Advisory Committee (2014-present).
- Member, NHMRC Research Translation Faculty (2012-present).
- President, Executive Committee, Society for Mental Health Research (2017-present).
- Member, Psychology Board of Australia, General Psychologist Registration Number PSY0001332657 (2010-present).
- President, Board of Directors, International Society for Research on Internet Interventions
- Chair, Research Committee, The Black Dog Institute, University of New South Wales (2017-present).
- Member, Research Strategy Committee, Orygen: The National Centre of Excellence in Youth Mental Health, University of Melbourne (2017-present).
- Academic Member, Human Research Ethics Committee, The University of Newcastle (2017-present).

Publications (2017-2018)

In press

Cunningham, J., Hendershot, C., Kay-Lambkin, F., Griffiths, K., Bennett, K., Bennett, A., Godinho, A., Schell, C. (in press). Does providing a brief Internet intervention for hazardous alcohol use to people seeking online help for depression reduce both alcohol use and depression symptoms among participants with these co-occurring disorders? Randomized controlled trial. *BMJ Open, Accepted 20 June 2018.*

2018


2017
Grants as Chief Investigator (2017-18)
  a) Batterham, P., Sunderland, M., Calear, A., Kay-Lambkin, F. Increasing engagement with online psychosocial programs to improve mental health in the community, National Health and Medical Research Council project grant (APP1138713). 2018-2020 $352,316.70

HDR Supervision (2017-2018)
9. Claire Young (Deakin, secondary, commenced 2017, full time). An online dietary intervention for people with depression.

Awards (2017-2018)

2018 - University of Newcastle
Vice-Chancellor’s Award for Research Supervision Excellence

2017 - Mental Health Council of NSW
Mental Health Promotion and Wellbeing Mental Health Matters Award
Positive Choices - Stapinski, Newton, Kay-Lambkin, Teessen, Allsop, McBride, Lawler & Grummit

2017 - Australian Rotary Health
Australian Rotary Health Knowledge Dissemination Award
Cracks in the Ice Online Toolkit
Chapman, C., Birrell, L., Champion, K., Stapinski, L., Kay-Lambkin, F., Deen, H., Brierley, M.E., Teesson, M., Newton, N.
Professor Murray Cairns  
Senior Brawn Fellow  
Commenced 2017


My research is directed towards understanding the molecular systems that regulate neural development, circuitry and plasticity. These mechanisms provide the biological foundation for learning and cognition but are also sensitive to genetic and environmental challenges that can lead to neurocognitive and neuropsychiatric disorders, such as schizophrenia. By investigating the molecular neurobiology of these complex systems and the syndromes that arise from their disruption, we have the potential to better understand human brain development and function. These steps also provide a strong basis for developing genetic and epigenetic biomarkers of brain disease and novel therapeutic strategies to defeat the most devastating neurocognitive disorders.

The research has been highly productive in the current reporting period with several publications in high impact journals including: *Science, Cell, Nature Genetics, Molecular Psychiatry, Biological Psychiatry and Nucleic Acids Research.*

I am a member of the PRC Brain and Mental Health Research

**Key Achievements**
I am an executive editor of *Genetics Research* and an editorial board member of *Epigenomics, American Journal of Medical Genetics, MicroRNA, Frontiers in Non-Coding RNA, Journal of RNAi and Gene Silencing, Open Journal of Genomics, Genomics, Proteomics & Bioinformatics* and *Recent Patents on Anti-Infective Drug Discovery.*

I have over 120 career publications including many in the highest-ranking journals in this field, with major publications in *Nature, Science, Cell, Nature Biotechnology, Nature Genetics, Nature Neuroscience, JAMA Psychiatry, American Journal of Psychiatry, Biological Psychiatry, Molecular Psychiatry, Schizophrenia Bulletin, Journal of Biological Chemistry, Human Molecular Genetics, American Journal of Pathology,* and *Pharmacology Reviews.* Collectively these have attracted more than 6868 citations (H-index=39, i10=81) with the top 10 papers having more than 3157 citations. I have 8 publications >200 citations, 19 with >100 citations and 32 with >50 citations. These high-impact studies are highlighted by recent work in schizophrenia where I am a leading authority on systems biology, non-coding RNA and the influence of post-transcriptional gene silencing.

During 2017/18 the group made further progress in developing a framework for high-resolution translational genomics using integrated systems biology. In this approach, the group use whole genome sequencing as a scaffold for integration of functional genomic data to capture a complete picture for personalised analysis of schizophrenia patients. This research project was support by a NSW Health
Collaborative Genomics Grant ($800,000), which enabled the group to sequence the entire genome of 500 participants in the Australian Schizophrenia Research Bank. A manuscript from this work has recently been accepted in Molecular Psychiatry. This research has provided an opportunity for involvement in several global collaborations in brain and behavioural genomics, including the genetics working group of the ENIGMA consortium for brain imaging; the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) consortium and the schizophrenia and PTSD working groups of the Psychiatric Genomic Consortium. My group is also participating in the establishment of a new global consortium for machine learning in psychiatry and the Medical Genome Reference Bank. This work has already led to several high-profile publications in Science, Nature Genetics, Nature Neuroscience and Biological Psychiatry.

In support of ongoing work, I was awarded a further $1.14 million from the NHMRC to integrate this data with epigenomic and phenotypic information. I was also awarded $647,345 from the NHMRC to investigate transcriptomic biomarkers of PTSD. Since 2017 I have been supported by an NHMRC Senior Research Fellowship. Further refinement in the group’s understanding of the function of non-coding variants is being achieved through the development of isogenic cell lines produced through RNA-guided genome editing using the CRISPR/Cas9 approach. This initiative in high-resolution functional genomics was established with a grant from the US based Brain and Behavioural Research Foundation, Independent Investigator Grant.

**Competitive Grants and Fellowships:**

- **ARC Linkage Infrastructure Equipment and Facilities:** Hawk et al. Access to the National Computing Infrastructure peak supercomputing facility. $900,000 (2017).
- **NHMRC Senior Research Fellowship:** Cairns MJ. Personalised genomics in precision medicine of psychotic illness. (APP1121474) $631,370 (2017-2021).
- **NHMRC Project Grant:** Cairns MJ, Green MJ, Carr V. Complete genomics for mechanistic insight and precision treatments of schizophrenia. (APP1147644) $1,149,208 (2018-2020).

**Publications:**


**Research Higher Degree Supervision**

I have supervised 11 PhD students to completion and am currently supervising 9 PhD students.
I am a health behaviour scientist with a strong track record in cancer prevention and control research. More recently, my program of research has focussed on developing and evaluating the effectiveness of innovative health behaviour change strategies for reducing health inequalities and improving the lifestyle and health risk factors of people in socially disadvantaged groups (including the unemployed or those on low income or government benefits, high levels of mental illness or substance abuse, homelessness and Aboriginal people).

These groups are challenging to engage in well-designed intervention research yet my innovative approach of partnering with social and health care delivery organisations (such as Anglicare, Salvation Army, Mission Australia, and drug and alcohol and mental health services) means I have quickly become an Australian leader in the field and increasingly recognised internationally. A major strength of my research is that it is highly translatable to public health policy and practice delivering clear and often immediate benefits to society. I have worked closely with service delivery and policy organisations like the Cancer Council NSW to enhance the sustainability of my research. No other applied researcher within Australia or overseas has focused on this range of socially disadvantaged groups.

I am affiliated with two Priority Research Centres (PRCs) – PRC for Stroke and Brain Injury (50% and member of the Executive) and PRC Brain and Mental Health. I am linked with the HMRI program in Brain and Mental Health.

Key Achievements

1. In 2017, I established the Oceania chapter of the peak international Society for Research in Nicotine and Tobacco (SRNT) which covers Australia, New Zealand and various Pacific nations. I am currently President of the chapter which works to ensure a voice for the Oceania region in the broader research society. The chapter will host the first SRNT conference in Australia in October 2019 in Sydney. I am chair of the organising committee for this exciting event.
2. I have been awarded the 2018 Australasian Professional Society for Alcohol and other Drugs (APSAD) Mentor Award. This award recognises the efforts I have made in establishing a Faculty Gender Equity Committee to support women in health and medicine, the mentoring programs I have developed for early and mid-career researchers and the success of my mentees and past students. For example, my current PhD student Ms Alexandra Denham was awarded a competitive Jennie Thomas Top Up Scholarship from HMRI in 2018.
3. I have been appointed Co-Chair of the Consumer and Community Involvement (CCI) committee of the NHMRC-MRFF funded Australian Health Research Alliance, representing NSW Regional Health Partners.
4. Invited keynote presentations:
   - Mental Health Clinical Collaborative, Queensland Health Forum, Brisbane, 30 October 2018.
   - International Argentina 2017 Global Alliance for Chronic Diseases (GACD) Annual Meeting, Buenos Aires, Argentina, Oct 2017

5. Invited Commentaries and Editorials:

• **Bonevski B** (2018). Why some researchers choose not to work with the tobacco industry. Response to: Hughes et al. Why we work with the tobacco industry. *Addiction.*


**Peer-reviewed publications**


2. **Bonevski, B.** (In press 2018). Response to: Hughes et al. Why we work with the tobacco industry. Why some researchers choose not to work with the tobacco industry. *Addiction.* (Invited letter to the editor).


**Conferences**

Presentations at: e-Mental Health International Conference 2018, Newcastle, Nov 2018 (Invited plenary presentation); APSAD 2018 Conference, Auckland, New Zealand, Nov 2018 (Symposium and oral presentations); MHCC Forum, Brisbane, Oct 2018 (Invited oral presentation); Society for Research on Nicotine and Tobacco (SRNT), Baltimore, USA, Feb 2018 (Oral presentation and poster presentation); Nicotine Addiction & Smoking Cessation Update Day, Glebe, NSW, Nov 2017 (Invited speaker); International Argentina 2017 Global Alliance for Chronic Diseases (GACD) Annual Meeting, Buenos Aires, Argentina, Oct 2017 (Invited
Society for Research on Nicotine and Tobacco (SRNT), Florence, Italy, March 8-11, 2017 (Symposium chair and symposium presentations)

Grants as a CI

- Royal Australian College of General Practitioners (RACGP). Design, delivery and evaluation of an educational intervention for GP registrars in reviewing older patients’ medication regimens and de-prescribing inappropriate medications. 2018-2019: $103,000. Professor Parker Magin, Professor Sarah Hilmer, Professor Mieke van Driel, Professor Billie Bonevski, Associate Professor Elizabeth Holliday, Associate Professor Christopher Etherton-Beer, Professor Neil Spike, Dr Rohan Kerr.
- Royal Australian College of General Practitioners (RACGP). Improving guideline compliance for prescription of benzodiazepines and related drugs in general practice registrars: a pragmatic trial employing a non-equivalent control groups design and post-intervention qualitative evaluation. 2018-2019: $102,000. Professor Parker Magin, Professor Mieke van Driel, Dr Simon Holliday, Professor Adrian Dunlop, Professor Bonevski, Associate Professor Elizabeth Holliday, Ms Amanda Tapley, Professor Neil Spike, Dr Rohan Kerr, Dr Andrew Davey.
- Hunter New England Local Health District. Exploring smoking cessation with alcohol and other drug treatment clients. 2018: $40,000. Professor Billie Bonevski, Doctor Olivia Wynne, Associate Professor Adrian Dunlop.

Higher Degree Research Students

PhD Completions
Ms Sam McCrabb, 2014-2018

PhD supervisor
Ms Eliza Skelton, 2014-2018 (thesis under review)
Ms Yael Bar Zeev, 2015-2019
Ms Ediane De Queiroz Andrade, 2017-2021
Mr Prince Atorkey, 2017-2021
Ms Sarah Perkes, 2017-2021
Ms Alexandra Denham, 2017-2021
Ms Eva Naznin, 2018-2020

Clinical Psychology Masters Completions
Mr Edward Murray
Mr Louis Silberberg

Clinical Psychology Masters
Ms Lisa Mackenzie
Dr Alistair Lum
Ms Rukshar Gobarani
**Research Area:** The endoplasmic reticulum (ER) is the essential cellular organelle for calcium storage, protein folding and maturation, as well as biosynthesis of lipid and sterol. ER homeostasis is disrupted by a number of cellular stress conditions, such as nutrient deprivation, hypoxia, and alterations in glycosylation status, leading to the accumulation of unfolded and/or misfolded proteins in the ER lumen, consequently causing a state of ‘ER stress’. The ER response to stress conditions is referred as the ‘unfolded protein response (UPR)’. It has outputs designed to couple the ER protein-folding capacity with demand so that the cell can survive and function.

Accumulating evidence indicates that pathologic conditions interfering with ER homeostasis give rise to chronic activation of the UPR, which contributes to the pathogenesis of many diseases ranging from pulmonary and cardiovascular diseases, to cancer, diabetes, viral infections and inflammatory diseases. Most importantly, key roles underlying multiple neurodegenerative diseases have been attributed to ER stress.

Our previous studies reported that the adaptive mechanisms of cancer cells to ER stress contributes to cancer treatment resistance. However, the function role of tumour ER stress on tumour microenvironment (the non-cancerous cells present in the tumour) remains unknown, whereas the latter has been established to play an important role in supporting the growth of cancer cells.

We have found that ER stress promotes neuronal outgrowth and differentiation. Intriguingly, neuronal cells cultured in conditioned medium from ER-stressed tumour cells become activated and undergo ER stress, suggesting that the stress signal can be transmitted from tumour cells into neurons. We would like to identify the functional significance of tumour-related ER stress on infiltrated nerve in the tumour microenvironment. This is of particular significance, as a number of chemotherapeutic reagents have been reported to induce ER stress while passing its toxicity to cancer cells. An enhanced ER stress signal caused by those drugs promotes nerve infiltration, which in turn fosters cancer growth and dissemination. Therefore, this study will significantly advance our understanding of the appropriate oncological management.

Moreover, the crucial role of ER stress in cancer related neuropathic pain will also be identified. Understanding the effect of ER stress on the generation and maintenance of cancer pain opens routes to exploit this system for therapeutic purposes and assist to increase cancer patients’ quality of life.

My research program is integrated into the research strategy of the Priority Research Centre (PRC) for Cancer of UON and that of the Cancer Research Program (CRP) of the Hunter Medical Research Institute (HMRI). This not only facilitates collaborations between my research team and other local cancer researchers, but also enables me to contribute my research expertise broadly to other cancer research programs in Newcastle.
Key Achievements

Publications


Grants

1. Chen Chen Jiang, Hubert Hondermarck, Lei Jin. Tumour ER stress is a significant driver of nerve infiltration and cancer related neuropathic pain. Faculty of Health and Medicine 2017 Strategic Pilot Grant. $10,000, 2018, University of Newcastle.

2. Chen Chen Jiang, Lei Jin. Oncogenic upregulation of the long noncoding RNA MAFG-AS1. HMRI project grant 2017. $20,000, 2017, HMRI


4. Lei Jin, Chen Chen Jiang. Targeting a master switch at the intersection of survival signaling pathways to improve therapeutic outcomes of melanoma. Faculty of Health and Medicine 2017 Strategic Research Pilot Grant. $2,500, 2017, University of Newcastle.

5. Chen Chen Jiang, the 3rd World Congress and Expo on Oncology & Radiology-2017, Faculty of Medicine travel grant, $2000, The University of Newcastle, 2017

6. Rick F. Thorne, …, Chen Chen Jiang, … Researcher Equipment Grant, The University of Newcastle, $50000, 2017

7. Chen Chen Jiang, the 3rd World Congress and Expo on Oncology & Radiology-2017, HCRA travel grant, $1000, HCRA, 2017

Conference attendance

1. Jiang C. C. Cooperativity of HOXAS and STAT3 is Essential for Transcriptional Activation of PD-L1, 2nd International Conference and Exhibition of Cancer & Therapeutics, San Diego, USA, 26th-28th, Nov, 2018. (Keynote Speaker; Organising committee member)


5. Jiang C. C. Cooperativity of HOXAS and STAT3 is Essential for Transcriptional Activation of PD-L1, 3rd World Congress & Expo on Oncology and Radiology, San Francisco, USA, 4th-6th, Dec, 2017 (Keynote Speaker)


7. Jiang C. C. Cooperativity of HOXAS and STAT3 is Essential for Transcriptional Activation of PD-L1, 9th World Congress of Melanoma & 14th International Congress of the Society for Melanoma Research, Brisbane, Australia, 18th-21st, October, 2017.
My research is focussed on asthma during pregnancy, which affects 12% of pregnant women in Australia. Exacerbations are a key clinical problem in this group, with at least one third of women having an exacerbation requiring medical intervention in pregnancy. My research investigates the characteristics, risk factors and mechanisms of exacerbations, and the consequences for maternal, perinatal and childhood health. I am involved in conducting randomised controlled trials to test interventions involving inflammation-based management of asthma, which have been shown to significantly reduce the exacerbation rate in pregnancy. My current NHMRC-funded multi-centre RCT (the Breathing for Life Trial) is testing whether this novel management strategy also reduces adverse perinatal outcomes among women with asthma. Follow-up of the resulting birth cohort is focussed on determining the long-term potential of inflammation-based management during pregnancy as a primary prevention strategy for childhood asthma. My research goal is to generate the evidence required to improve clinical practice in the area of asthma management during pregnancy. My research is already informing practice by its inclusion in information papers and guideline documents, such as the Australian Asthma Handbook (2014, National Asthma Council of Australia), where 9 of my publications were cited in the section on pregnancy (asthma advice, asthma care and flare-ups).

I am one of the 12 key researchers in the University of Newcastle’s Priority Research Centre GrowUpWell™ (2016-2020) and I am a member of the HMRI VIVA Program.

Key Achievements
Invited presentations:

2018 Publications:


Invited publications:

2018 Grants:
2. University of Newcastle Faculty of Health and Medicine Research and Teaching Pilot Grant. Booster Babies: Reducing the impact of neurodevelopmental disorder in infancy. Alison Lane, Linda Campbell, Vanessa Murphy, Frini Karayanidis ($9500).

2018 HDR Supervision:
1. Karen McLaughlin – PhD (Medicine) at University of Newcastle, commenced 2/7/2015. Primary Supervisor (50%), with co-supervisors Prof Kirsten McCaffery (University of Sydney, 30%), Prof Maralyn Foureur (University of Technology Sydney, 10%) and Dr Megan Jensen (University of Newcastle, 10%). Assessing acceptability of a novel antenatal asthma management approach for pregnant women.
2. Patricia De Gouveia Belineo – PhD (Paediatrics) at University of Newcastle, commenced in March 2016. Co-supervisor (30%) with Prof Joerg Mattes (primary supervisor), Dr Adam Collison. Risk factors for impaired lung function and the onset of respiratory disease in early life.
3. Nisreen Al-Saedi – PhD (Medicine) at University of Newcastle, commenced November 2016. Principal supervisor (45%), with Dr Katie Baines (45%) and Dr Megan Jensen (10%). Inflammatory gene expression profiling during pregnancy to predict future asthma exacerbations and poor maternal and neonatal outcomes.
4. Carly Mallise – PhD (Psychology – Science) at University of Newcastle, commenced supervision March 2017. Co-supervisor (10%) with A/Prof Alison Lane, Dr Linda Campbell, A/Prof Frini Karayanidis. An investigation of infant temperament and maternal parenting stress as early markers for risk of autism spectrum disorder at one year of age.
5. Annelies Robijn – PhD (Medicine) at University of Newcastle, commenced supervision June 2017. Primary supervisor (60%) with Dr Megan Jensen (40%). Attitudes and adherence to asthma medication during pregnancy.
6. Soriah Harvey – PhD (Medicine) at University of Newcastle, commenced supervision Nov 2017. Co-supervisor (40%) with Dr Megan Jensen (50%, primary supervisor) and Prof Peter Gibson (10%). Maternal and early life nutritional status and respiratory health outcomes of the offspring.

7. Olivia Whalen – PhD (Psychology) at University of Newcastle. Commenced supervision February 2017. Co-supervisor (20%) with Prof Frini Karayanidis, Dr Linda Campbell and A/Prof Alison Lane. The role of infant and maternal factors on infant cognitive development.

8. Ediane De Queiroz Andrade – PhD (Paediatrics) at University of Newcastle. Commenced supervision June 2018. Co-supervisor (10%) with Prof Joerg Mattes (50%), A/Prof Gillian Gould (20%), Prof Billie Bonevski (10%), Dr Adam Collison (10%). Smoking cessation treatment in pregnant women and its impact on their offspring’s lung function.
Research area: Musculoskeletal health, chronic disease prevention and Implementation science and health services research

My work focuses on improving the coordination of population health and clinical services to optimise prevention and management of health risk factors associated with non-communicable disease and musculoskeletal conditions in adults and adolescents. This work is applied through studies that test: i) the clinical effectiveness of clinical and public health interventions to improve health outcomes; and ii) the effectiveness of strategies to improve the adoption and sustained use of recommended practice in community and clinical settings.

Up to 90% of the population experience musculoskeletal disorders, such as low back or neck pain or osteoarthritis of the hip or knee, in their lifetime. Patients with musculoskeletal conditions have higher rates of comorbid health risks such as obesity, inactivity and substance use behaviours (tobacco and alcohol). Unfortunately few people with musculoskeletal conditions receive recommended care, including support to manage health behaviour risks.

My research in this area in 2017 and 2018 has involved implementation of a co-ordinated care model to facilitate the management of health behavioural risks in patients with musculoskeletal pain. This work involved a longitudinal cohort study to monitor patient health over time and two randomised controlled trials to test the effectiveness of the co-ordinated care to reduce weight in patients with back and knee pain. The work has led to an NHRMC project grant being awarded to conduct a larger RCT. The new study will extend to other settings (e.g. primary care) to implement a more comprehensive care model targeting multiple risk factors, earlier in the patients care.

I am a member of the PRC in Health Behaviour. I am linked with the HMRI program in Public Health.

Key Achievements:
To date my work has involved local, as well as state, national and international agencies including; WHO, RACGP, NPS Medicine Wise, and NSW Government. I have authored 85 journal papers, with publications in leading general medical journals such as Lancet, British Medical Journal, PLoS Medicine, JAMA Internal Medicine, and BMC Medicine.

In 2018, I have served as Chair for the HMRI EMCR Ignite Initiative. I was Associate Editor of Trials and worked as part of an Australia Clinical Trials Alliance working group for embedding clinical trials in practice. I was invited to present at 4 international and national conferences as a plenary speaker. In 2017-2018, I published 31 peer reviewed papers, and my citation rate doubled. My research group completed and published two high quality randomised controlled trials published in leading content specific journals (PAIN IF5.6, Osteoarthritis and cartilage, IF 4.1). Two of my PhD students completed their PhD in 2018.
Publications:

HDR Supervision:
Doctor of Philosophy, Amanda Williams, University of Newcastle (completed 2018)
Doctor of Philosophy, Kate O’Brien, University of Newcastle (completed 2018)
Doctor of Philosophy, Nicola McLaren, University of Newcastle (2015 -)
Doctor of Philosophy, Emma Robson, University of Newcastle (2017 -)
Doctor of Philosophy, Priscilla deSilva University of Newcastle (2018 - )
Doctor of Philosophy, Simon Davidson, University of Newcastle (2018 - )
Master of Philosophy, Karen Grainey, University of Sydney (2018 - )

Prizes:
HNELHD winner Excellence Awards (and State finalists) – for Integrated Care (with Outpatient Services)
### Gladys M Brawn Bequest Brawn

**Financial Report**

**As at 31\textsuperscript{st} December 2018**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening Balance 1/1/18</td>
<td>$10,636,157.78</td>
</tr>
<tr>
<td>Interest Available for Expenditure (2018)</td>
<td>$462,445.00</td>
</tr>
<tr>
<td>Total Expenditure 31/12/18</td>
<td>$462,445.00</td>
</tr>
<tr>
<td>Opening Balance 1/1/19</td>
<td>$11,063,684.86</td>
</tr>
<tr>
<td>Interest Available for expenditure (2019)</td>
<td>$329,628.00</td>
</tr>
</tbody>
</table>
Gladys M Brawn Gravesite
Gladys M Brawn Gravesite

In keeping with the Deed’s request, annual site visits occur to ensure that Gladys Brawn’s gravesite is in good upkeep and any necessary maintenance is organised. The gravesite is located in Kurri Kurri Cemetery. The last visit occurred on the 2 November 2018.
Glossary of Terms

Grant Funding – total grant amount awarded over its lifetime.

IF – Impact Factor of the Journal where publication has been published. The Impact Factor is a measure reflecting the average number of citations to recent articles published in the journal. It is frequently used as a proxy for the relative importance of a journal within its field, with journals with high impact factors deemed to be more important than those with lower ones.

Indicative Research Earnings - income the University earns from grants awarded, papers published and Higher Degree Research (HDR) supervision, notionally allocated to the researcher.

Research Income – HERDC (Higher Education Research Data Collection) reportable research income.

CI – Chief Investigator